



US 20050188429A1

(19) **United States**

(12) **Patent Application Publication**

Auernhammer et al.

(10) **Pub. No.: US 2005/0188429 A1**

(43) **Pub. Date: Aug. 25, 2005**

(54) **METHOD FOR TREATING A CONDITION WITH A CYTOKINE OF THE GP130 SUBUNIT SIGNALING FAMILY LINKED TO A POLYNUCLEOTIDE ENCODING SOCS-3**

Publication Classification

(51) **Int. Cl.⁷ A01K 67/027**

(52) **U.S. Cl. 800/19; 435/325**

(75) **Inventors: Christoph J. Auernhammer, Munchen-Pasing (DE); Shlomo Melmed, Los Angeles, CA (US)**

(57) **ABSTRACT**

Correspondence Address:
**DAVIS WRIGHT TREMAINE LLP
865 FIGUEROA STREET
SUITE 2400
LOS ANGELES, CA 90017-2566 (US)**

Disclosed is a nucleic acid construct comprising a murine SOCS-3 promoter sequence having SEQ. ID. NO.:1, or a non-murine homologue thereof, or an operative fragment or derivative. The construct can also contain, operatively linked to the SOCS-3 promoter, a gene encoding any pre-selected protein, and optionally contains a reporter gene to facilitate detection and/or selection of successfully transfected cells. Also disclosed are a transgenic vertebrate cell containing the nucleic acid construct and transgenic non-human vertebrates comprising such cells. The nucleic acid construct is useful in methods of treating a growth retardation or growth acceleration disorder in a human subject and in a method of treating an autoimmune disease, immune disease, or inflammatory condition in a human subject. A kit for genetically modifying a vertebrate cell includes a polynucleotide comprising the murine SOCS-3 promoter sequence is also disclosed.

(73) **Assignee: Cedars-Sinai Medical Center, Los Angeles, CA**

(21) **Appl. No.: 11/092,026**

(22) **Filed: Mar. 29, 2005**

Related U.S. Application Data

(62) **Division of application No. 10/136,224, filed on Apr. 29, 2002, which is a division of application No. 09/327,138, filed on Jun. 7, 1999, now Pat. No. 6,541,244.**




FIG. 1A




FIG. 1B




FIG. 2D

FIG. 2A




FIG. 2C




FIG. 2B




FIG. 2F




FIG. 2E




FIG. 3

METHOD FOR TREATING A CONDITION WITH A CYTOKINE OF THE GP130 SUBUNIT SIGNALING FAMILY LINKED TO A POLYNUCLEOTIDE ENCODING SOCS-3

[0001] The U.S. Government has a paid-up license in this invention and the right in limited circumstances to require the patent owner to license others on reasonable terms as provided for by the terms of grant DK 50238 awarded by the NIH.

[0002] Throughout this application various publications are referenced within parentheses. The disclosures of these publications in their entireties are hereby incorporated by reference in this application in order to more fully describe the state of the art to which this invention pertains.

BACKGROUND OF THE INVENTION

[0003] 1. The Field of the Invention

[0004] This invention relates to the medical arts. In particular the present invention relates to the field of cellular signal transduction and to gene therapy.

[0005] 2. Discussion of the Related Art

[0006] Cytokines are small secreted proteins or factors (5 to 20 kD) that have specific effects on cell-to-cell interactions, intercellular communication, or the behavior of other cells.

[0007] Cytokines involved in inflammatory diseases are produced by lymphocytes, especially T_H1 and T_H2 lymphocytes, monocytes, intestinal macrophages, granulocytes, epithelial cells, and fibroblasts. (Reviewed in G. Rogler and T. Andus, *Cytokines in inflammatory bowel disease*, World J. Surg. 22(4):382-89 [1998]; H. F. Galley and N. R. Webster, *The immuno-inflammatory cascade*, Br. J. Anaesth. 77:11-16 [1996]). Some cytokines are pro-inflammatory (e.g., tumor necrosis factor [TNF]- α , interleukin [IL]-1(α and β), IL-6, IL-8, IL-12); others are anti-inflammatory (e.g., IL-1 receptor antagonist [IL-1ra], IL-4, IL-10, IL-11, and transforming growth factor [TGF]- β). However, there may be overlap and functional redundancy in their effects under certain inflammatory conditions.

[0008] One group of cytokines, the IL-6-type, are also important in the regulation of complex cellular processes such as gene activation, proliferation and differentiation. The IL-6-type cytokines include IL-6, IL-11, leukemia inhibitory factor (LIF), oncostatin MK ciliary neurotrophic factor, and cardiotrophin-1. (Reviewed in P. C. Heinrich et al., *Interleukin-6-type cytokine signaling through the gp130/JAK/STAT pathway*, Biochem. J. 334(Pt 2):297-314 [1998]). The IL-6-type cytokines (also known as the gp130 signaling subunit cytokine family) have in common that signal transduction proceeds through a pathway beginning with ligand binding by type I and type I surface receptors, internalization involving affinity converter/signal transducing subunit gp130, the activation of the Janus family of cytoplasmic tyrosine kinases (e.g., Jak1, Jak2, and Tyk2); this results in the phosphorylation and dimerization of the signal transducers and activators of transcription (STAT-1 and STAT-3 that activate transcription from promoters having STAT recognition sites. (Heinrich et al. [1998]; M. Ernst et al., *Gp130-mediated signal transduction in embryonic stem cells involves activation of Jak and Ras/mitogen-activated protein*

kinase pathways, J. Biol. Chem. 271(47):30136-43 [1996]; R. Starr et al, *A family of cytokine-inducible inhibitors of signaling*, Nature 387(6636):917-21 [1997]; T. Hirano et al., *Cytokine & Growth Factor Rev.* 8:241-52 [1997]; E. Arzt & G. K. Stalla, *Neuroimmunomodulation* 3:28-34 [1996]; S. J. Haque & B. R. G. Williams, *Semin. Oncol.* 25 (suppl. 1):14-22 [1998]). This pathway is known as the Jak-STAT signaling cascade.

[0009] Several IL-6-type cytokines are important neuro-immuno-endocrine modulators of the hypothalamo-pituitary-adrenal (HPA) axis (Arzt, E. & Stalla [1996]; S. Melmed, *Trends Endocrinol. Metab.* 8:391-97 [1997]; H. O. Besedovsky, & A. Del Rey, *Endo. Rev.* 17:64-102 [1996]), which regulates metabolism, including growth, body temperature, water balance, blood sugar, fat metabolism, and sexual and nerve function. For example, LIF is a potent auto-paracrine stimulus of pituitary proopiomelanocortin (POMC) gene expression and adrenocorticotrophic hormone (ACTH) secretion, which stimulates the adrenals to produce additional hormones. Thus, LIF modulates the HPA axis response to various inflammatory and stress stimuli. (Z. Wang et al., *Endocrinology* 137:2947-53 [1996]; C. J. Auernhammer et al., *Endocrinology* 139:2201-08 [1998a]). In vitro experiments using human fetal pituitary cells (I. Shimon et al., *J. Clin. Invest.* 100: 357-63 [1997]) and the corticotroph cell line AtT-20 (S. Akita et al. *J. Clin. Invest.* 95, 1288-1298 [1995]; C. Bousquet et al., *J. Biol. Chem.* 272:10551-57 [1997]), showed a profound and synergistic action of LIF and corticotropin-releasing hormone (CRH) on POMC gene expression and ACTH secretion. LIF is known to induce the Jak-STAT signaling cascade in the corticotroph cells. (C. J. Auernhammer et al., *Pituitary corticotroph SOCS-3: novel intracellular regulation of leukemia-inhibitory factor-mediated proopiomelanocortin gene expression and adrenocorticotropin secretion*, Mol. Endocrinol. 12(7):954-61 [1998b]; I. Shimon et al. [1997]; D. W. Ray et al., *Leukemia inhibitory factor (LIF) stimulates proopiomelanocortin (POMC) expression in a corticotroph cell line. Role of STAT pathway*, J. Clin. Invest. 97(8):1852-59 [1996]; D. W. Ray et al., *Ann. N.Y. Acad. Sci. USA* 840:162-73 [1998]).

[0010] A new family of cytokine-inducible proteins has recently been described that inhibits the Jak-STAT signaling cascade. (E.g., S. E. Nicholson et al., *The SOCS proteins: a new family of negative regulators of signal transduction*, J. Leukoc. Biol. 63(6):665-68 [1998]; R. Starr et al., *SOCS: suppressors of cytokine signaling*, Int. J. Biochem. Cell. Biol. 30(10): 1081-85 [1998]). These proteins have been variously termed suppressors of cytokine signaling ("SOCS") (R. Starr et al., *A family of cytokine-inducible inhibitors of signaling*, Nature 387(6636):917-21 [1998]; D. J. Hilton et al., *Proc. Natl. Acad. Sci. USA* 95:114-19 [1998]), STAT-induced STAT inhibitors (SSI) (T. Naka et al., *Nature* 387:924-28[1997]; S. Minamoto et al., *Biochem. Biophys. Res. Commun.* 237:79-83 [1997]), cytokine-inducible SH2 containing protein (CIS) (A. Yoshimura et al., *EMBO J.* 14:2816-26 [1995]; M. Masuhara et al., *Biochem. Biophys. Res. Commun.* 239:43946 [1997]; A. Matsumoto et al., *Blood* 89:3148-54 [1997]), and Jak binding protein (JAB) (T. A. Endo et al., *Nature* 387:921-24 [1997]; H. Sakamoto et al., *Blood* 92:1668-76 [1998]). The SOCS-protein family currently consists of CIS and SOCS-1 through 7. (D. J. Hilton et al. [1998]; M. J. Aman & W. J.

Leonard, *Curr. Biol.* 7:R784-R788 [1997]; R. Starr & D. J. Hilton, *Int. J. Biochem. Cell Biol.* 30:1081-85 [1998].

[0011] SOCS-protein expression is stimulated by various cytokines in a tissue specific manner (R. Starr et al., *Nature* 387:917-21 [1997]; M. J. Aman & W. J. Leonard [1997]; H. Sakamoto et al. [1998]; H. O. Besedovsky, & A. Del Rey [1996]; T. E. Adams et al., *J. Biol. Chem.* 273:1285-87 [1998]; C. Bjorbaek et al., *Mol. Cell* 1:619-625 [1998]). The gene expression of SOCS-1/SSI-1/JAB and SOCS-3/SSI-3/CIS-3, referred to herein as SOCS-1 and SOCS-3, are induced by IL-6 and LIF in various tissues (R. Starr et al. [1997], D. J. Hilton et al. [1998]; T. Naka et al. [1997]; S. Minamoto et al. [1997]; M. Masuhara et al. [1997]; A. Matsumoto et al. [1997]; T. A. Endo et al. [1997]). For example, SOCS-3 gene expression is rapidly induced by LIF in the pituitary in vivo, and in corticotroph AtT-20 cells in vitro. (C. J. Auernhammer et al. [1998b]).

[0012] Both, SOCS-1 and SOCS-3 proteins bind to the JH1 domain of Jak-2 and thereby inhibit IL-6-, IL-11-, or LIF-induced tyrosine phosphorylation activity by Jak-2 of gp 130 and STAT-3. (S. Minamoto et al. [1997]; M. Masuhara et al. [1997]; C. J. Auernhammer et al. [1998b]). SOCS-3 is induced by growth hormone (GH) in the liver, and inhibits GH-induced Spi 2.1 promoter activity. (T. E. Adams et al. [1998]). SOCS-3 inhibits LIF-induced POMC gene expression and ACTH secretion (C. J. Auernhammer et al. [1998b]), thus providing an intracellular negative feedback regulation of cytokine-induced activation of the HPA-axis. Hypothalamic SOCS-3 gene expression is stimulated by leptin, and SOCS-3 inhibits leptin-induced signal transduction (C. Bjorbaek et al., *Mol. Cell* 1:619-625 [1998]), thus suggesting its regulatory role in central leptin resistance.

[0013] The structure of SOCS proteins has been described. (e.g., S. E. Nicholson et al., *Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction*, *EMBO J.* 18(2):375-85 (January 1999). Dominant negative STAT-3 mutants, isolated by substitution of a carboxy-terminal tyrosine phosphorylation site Tyr⁷⁰⁵ to Phe⁷⁰⁵ (STAT-3F) or mutation at positions important for DNA binding (STAT-3D) have been recently described (K. Nakajima et al., *EMBO J.* 15:3651-58 [1996]). Overexpression of these STAT-3 dominant negative mutants in corticotroph AtT-20 cells inhibits LIF-induced POMC gene expression and ACTH secretion. (C. Bousquet & S. Melmed, *J. Biol. Chem.* 274:10723-30 [1999]). Cytokine-induced gene expression of SOCS-1 has been shown to be inhibited in cells overexpressing dominant negative STAT-3 mutants (T. Naka et al. [1997]), but the promoter region of SOCS-1 has not been cloned.

[0014] Therefore, there remains a definite need for a promoter sequence capable of regulating expression of pre-selected proteins, such as SOCS-3 protein, and that can be targeted by gene therapy to treat growth disorders, autoimmune diseases, immune diseases, and inflammatory conditions. This and other features and benefits provided by the present invention will now be described.

SUMMARY OF THE INVENTION

[0015] The present invention relates to a nucleic acid construct comprising a murine SOCS-3 promoter sequence,

or a non-murine homologue thereof, or an operative fragment or derivative of any of these. The construct can also contain, operatively linked to the SOCS-3 promoter, a DNA sequence encoding a gene for any preselected protein or a gene-specific part of such a DNA sequence, or to a DNA sequence that encodes a preselected gene-specific antisense RNA or a catalytic RNA. A preselected protein that is encoded by the nucleic acid construct can be from an autologous, allogeneic, or xenogeneic source. In addition, the present nucleic acid construct optionally contains a reporter gene to facilitate detection and/or selection of successfully transfected cells. The present nucleic acid construct is particularly useful for linking expression of a desired gene product to physiological processes that are regulated by gp130-mediated signal transduction from IL-6-type cytokines (i.e., cytokines of the gp130 signaling subunit cytokine family), such as IL-6, IL-11, or LIF. For example, when the encoded protein is a SOCS-3 protein, the present nucleic acid can be used to modulate the physiology and/or hormonal secretions of cells of the hypothalamus, pituitary, adrenals, liver, or other tissues, through a negative autoregulatory feedback of SOCS-3 on its own cytokine-induced gene expression.

[0016] The present invention also relates to a transgenic vertebrate cell containing the nucleic acid construct of the present invention and to transgenic non-human vertebrates comprising such cells.

[0017] The present invention also relates to a method of treating a growth retardation disorder in a human subject. The method involves genetically modifying a GH-responsive or gp130-responsive cell(s) of a human subject having a growth retardation disorder, such as dwarfism, GH deficiency, gonadal dysgenesis, chondrodystrophy, or bone-cartilage dysplasia. The cell(s) are genetically modified using a nucleic acid construct that comprises a SOCS-3 promoter sequence, or operative fragment thereof, operatively linked to a DNA sequence that encodes an RNA that specifically hybridizes to a functional SOCS-3 mRNA. In response to a growth-inducing cytokine, in vivo, the genetically modified cell(s) within the human subject, transcribe an RNA transcript that specifically hybridizes to a functional SOCS-3 mRNA, preventing translation therefrom. This RNA transcript can be an antisense RNA or a catalytic RNA (ribozyme) that cleave the SOCS-3 mRNA. As a consequence, the amount of SOCS-3 protein produced within the genetically modified cell(s) is relatively reduced, and one or more symptoms of the growth retardation disorder in the subject are thereby improved, due to a lessening of SOCS-3-mediated signal suppression within the genetically modified cell(s).

[0018] The present invention also relates to a method of treating a growth acceleration disorder in a human subject. The method involves genetically modifying a GH-responsive or gp130-responsive cell(s) of a human subject having a growth acceleration disorder, such as gigantism, acromegaly, or Cushing's disease. The cell(s) are genetically modified using a nucleic acid construct, comprising a SOCS-3 promoter sequence, or operative fragment thereof, operatively linked to a DNA sequence encoding a SOCS-3 protein, or functional fragment thereof. In response to the growth-inducing cytokine, in vivo, the genetically modified cell(s) produce an enhanced amount of SOCS-3 protein. The symptom(s) of the growth acceleration disorder in the sub-

ject are thereby improved, due to enhanced SOCS-3-mediated cytokine signal suppression.

[0019] The present invention also relates to a method of treating an autoimmune disease, immune disease, or inflammatory condition in a human subject having a condition, such as Crohn's disease, ulcerative colitis, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, Grave's disease, or a neuroendocrinological response to psychological or physical stress. The method involves genetically modifying a gp130-responsive cell(s), responsive to a pro-inflammatory cytokine, such as IL-6 or LIF. The cell(s) are genetically modified using a nucleic acid construct that includes a SOCS-3 promoter sequence, or operative fragment thereof, operatively linked to a DNA sequence encoding a SOCS-3 protein, or functional fragment thereof. In response to a pro-inflammatory cytokine of the gp130 signaling subunit cytokine family, in vivo, the genetically modified cell(s) produce an enhanced amount of SOCS-3 protein. The symptom(s) of the autoimmune disease, immune disease, or inflammatory condition in the subject are thereby improved, due to a relative increase in SOCS-3-mediated signal suppression.

[0020] Alternatively, the SOCS-3 promoter is operatively linked to a DNA sequence encoding a functional anti-inflammatory cytokine of the gp130 signaling subunit cytokine family, such as IL-11, linked to a functional secretory signal. In response to a pro-inflammatory cytokine of the gp130 signaling subunit cytokine family, in vivo, the genetically modified cell(s) produce and secrete an enhanced amount of the anti-inflammatory cytokine. The symptom(s) of the autoimmune disease, immune disease, or inflammatory condition in the subject are thereby improved.

[0021] The present invention also relates to a kit for genetically modifying a vertebrate cell. The kit includes a polynucleotide comprising a murine SOCS-3 promoter sequence having SEQ. ID. NO.:1, or an operative fragment or non-murine homologue thereof, or an operative derivative of any of these. Preferably, the polynucleotide includes, operatively linked to the SOCS-3 promoter, at least one DNA sequence encoding a preselected protein or a gene-specific part of such a DNA sequence, or a DNA encoding a preselected gene-specific antisense RNA or a specific catalytic RNA, as appropriate for a particular application. Optionally, the promoter is linked to a reporter gene for facilitating detection, isolation, or selection of genetically modified cells from unmodified cells. Some embodiments of the kit are configured for use in practicing the present methods of treating a growth retardation or acceleration disorder in a human subject or the present method of treating an autoimmune disease, immune disease, or inflammatory condition in a human subject.

[0022] These and other advantages and features of the present invention will be described more fully in a detailed description of the preferred embodiments which follows.

BRIEF DESCRIPTION OF THE DRAWINGS

[0023] FIG. 1 shows stimulation of expression from the murine SOCS-3 promoter in corticotroph AtT-20 cells treated with 0.5×10^{-9} M LIF, IL-6, or IL-11 for 60 and 120 min, respectively. FIG. 1A shows a Northern blot analysis performed with 25 μ g total RNA per lane. The upper panel shows SOCS-3 mRNA; the lower panel shows β -actin mRNA. FIG. 1B shows luciferase activity in AtT-20 cells transfected with pGL3Basic alone or a -2757/+929 murine SOCS-3 promoter-pGL3Basic construct (clone 6).

[0024] FIG. 2 shows LIF-induced SOCS-3 promoter activity and gene expression in corticotroph AtT-20 cells overexpressing wild type STAT-3 (AtT-20W) or dominant negative STAT-3 mutants (AtT-20F and AtT-20D), as well as wild type SOCS-3 (AtT-20S) and mock-transfected (AtT-20M); cells were treated with 0.5×10^{-9} M LIF for 45 min. FIGS. 2A and 2D show Northern blot analysis performed with 15 μ g total RNA per lane for a representative experiment; upper panel shows SOCS-3 mRNA; lower panel shows β -actin mRNA. FIGS. 2B and 2E show Northern blot signals for SOCS-3 mRNA analyzed by quantitative densitometry and normalized for β -actin mRNA. FIGS. 2C and 2F show relative luciferase activity in various cell clones bearing a -2759/+927 murine SOCS-3 promoter-pGL3Basic construct (clone 6).

[0025] FIG. 3 shows relative luciferase activities in transiently transfected AtT-20 cells bearing different constructs of the genomic 5'-region of murine SOCS-3. Luciferase activity was measured in untreated (filled bars) and LIF-stimulated (unfilled bars) AtT-20 cells. Crossed lines indicate a deletion of STAT binding elements in Clone 6D1 and 6D2, in between the named nucleotides. A dotted line indicates a mutation of the wild type STAT binding sequence (5'-TTCCAGGAA-3'; SEQ. D. NO: 13) with mutant (5'-ATCGACGAT-3'; SEQ. ID. NO.: 14) in clone 6M1.

DETAILED DESCRIPTION OF THE SPECIFIC EMBODIMENTS

[0026] The present invention relates to a nucleic acid construct comprising a murine SOCS-3 promoter sequence, or an operative fragment thereof, or a non-murine homologue thereof, or an operative derivative of any of these.

[0027] The following nucleotide sequence represents the full length ~3.8-kb genomic 5'-region of the murine SOCS-3 gene (GenBank Accession AF117732). The transcription start site is defined as +1. An untranscribed region extends from nucleotide -2907 to -1, inclusive. A transcribed but untranslated region (exon 1) extends from +1 to +289; exon 2, begins at +854 (exons are underlined), and contains the intronless coding region of SOCS-3 with a translational start site encoded at nt. +944 to +946. (R. Starr et al. [1997]). The translation initiation codon ATG (nt. +944 to +946) and a TATA-box (nt. -39 to -34) are indicated in boldface type. Two potential STAT-binding elements (nt. -74 to -66 and nt. -97 to -88) are in boldface and underlined:

```
-2907 GACGTTCCCTA AAAGCATGCA TGTCACCCAG CTTACCCACC CATCTCAGGC CACAGCAGCC (SEQ. ID. NO.:1)
-2847 TGAGAGAGCG GAAGAACACC TGCTGGTCTT GTCCACCTC TCCTCTTCAA ACAGCCCCAC
-2787 ATCCTCCAGT TTTGCTCTGG GTGGAGCTCC CTGCTGGCCC TGCAGAGGGA AGGCTCTCCT
```

-continued

-2727 AAGCATCATC TATCAGAACG TCTTCAAAAA AAAAAAAAAA AAAAAAAAAAG CCTCTCCAGC
-2667 CAGGCTAGCT CTAACACCAT TTCTTCCCCT TCCCCTCTCT CAAATTCACT TATCTTTTTT
-2607 TTTTTTTTTT TTTTGGATT TTTGAGACAG GGTTCCTCTG TATAGCCCTG GTTGTCTGG
-2547 AACTCACTTT GTACACCAGC CTGGCCTCGA ACTCAGAGAT CCACCTGCCT CTGCCTCCTG
-2487 AGTGCTGGGA TTAAAGGCGT GCGCCACCAC GCCCGGCTAA ATTCACTTAT CTATTTAATG
-2427 TATATAGGGT ATAGGCTGCC CTTGAACCTA CAAAGATCTG CTTGCTTTGC TTCTGGAATA
-2367 CTAAGGTGT GTGCTACCAT CACAGGGACC AAGATTTATT TTAATTCTGT ATATGTGTGT
-2307 GTGTGTGTGT GTGTATGGGG GGTGCACATG AGTACAGATT CCCTGGAGG CCTGGGGTGG
-2247 CTTAGGACTG GGGTTACAAC AGTTGTGACC CATCCTACAT AGTCTCTGGC ACCAACACCC
-2187 CCCCCCCCCC CCCCCTCTT CCAGAAGTGC AGCAGGTGTT CTTAAGTGTG GAGCCAGCAA
-2127 TCCAGCCCCT GACTTCCCCT TCTTACTTAA GAAGCTATCA CAGTGTCTCA CTGGGTGACA
-2067 ATCATGACTA GTCCCTTGCTC ATGGCCACACA GCCTCTTCCC CACTGTGGGT TTTGCCCCGC
-2007 AGCTCTGCCG CCCCAGCGCT GCACCCGAGG CCTGACAGAG CCAGGCACGA AGTCAGGGTT
-1947 TGTGGAATGG ATGAATGAAC TTGACTCGTG GCAGAGCATT GTAATTTACA AAGCACTTTC
-1887 CCATCCATTA ACTCCAGGGC TATTTCTTAA GAGTCTCCC TGTCTCCAC TGCCCTCGGC
-1827 TCAGAGGCAT ACGGTCAAGG CAGTGGCTGG GGAACACTCC CTGAATGAGA TCAAGGAGGG
-1767 CTTGTTTACA GAGAAAGGGA GAATCCATTT GGGGAGCCTG AGAGTGACTC GAAGGCAAGG
-1707 ACTGGGCCCT ACCTGTGGGA TCTCCATCTG TGAGCATCCG CTCATCAGAC CAGTGTGAGA
-1647 TATTTTAAAT AAGGCCCTTA AGCCTCTTGA CTAAGTGAAT TGCCAGGGGC GGGGGACAGA
-1587 TGGGACCCCA TCCCTATTTA ACAGATAACA AGACTGAGTC CAGAGAGGCA GTGCACCTGC
-1527 CCTGGTCTCT CTTAGTTTCT CAGCATCAGT GGAGCAGATT GGACACAGTG GGCCAGAAGG
-1467 GAAGCAGGCA GCCCTCCCCTC CTAGCCCAGG CTAAGTCTGTG TAGTCAGTTT GCCCTCTAC
-1407 TGGTGTTACA AGAAGCCTCT GGTATCCAAG AGGGCAGGTC AGAAAGCCCA CTGAGAGCAG
-1347 ACACGTGTG TCACCTAGCT GGTTCCTCAG TGGCTGCCAC TTCCTGCTGC CTGTTGCAAA
-1287 ACTCGACACT AGGCCCTTAT AGATACTCAC GTGACCAGGA GTAAACAACC TTTCACCTCA
-1227 ATCACCTGCT CTTATCAATA CTCCCTCTCC ACCCCACCAT CGGGAAAGTT CAGACACCTT
-1167 AAAACGTAGA GGCAAGAGAG GGTCCATTCT GACACCTCAG CACTTTCAG GCAGTGGCTG
-1107 AACCCGTTAC AACGCTCTGT GGACAGTCTT CCTAGTCGAC ATTCTTCTC AGGTTTGACC
-1047 CTGTCTGGG AAGTGGAGCT TCTCTCTCTG GGTTCCTCAC TCCTGTCTCT GAATAAGGAG
-987 CCCCACAACC TCTTATTCTC TCTATACAGA GCCTGGGAAA CAGCAAAACT CGGCTCGCCT
-927 ACAAGACTCC AGCGCGCCCT CTGGTGGACT CGGGGGACGA GCATGGGATG AGGGTTTCTT
-867 TCCTCTAGCT CCCCCACCGC GCCGAGAGTA CCTGGGCGGA CCCACAGTTC GCCACGCAGG
-807 TTGGGAGGCC CAGATGAGTG ATAAGGTAGT AGTTAGTGC TCCTCCCACC CCACTCCCA
-747 AAGGACATCA GCACCCACGT CTGTACCGA AGAACCAGGC AATGGGCGGA TGAGCTGAGG
-687 CCAGGTAGCT GCTTCTAAGT CAGTGTCTCC TCCACTTCTG GATCTCACAG CTTCATCTTT
-627 TGGACTGTG TACAGGTAAT TGTCGCGCAT CCCCTCCTC CACTTCTAG GTCCCCAGTG
-567 GGCTGGTGGC TGAATGGTCC TACGTCCCTT TTGGTTGGCA CGGGATGCTT GGAAGTGTAC
-507 ATGAGGACCT CGGGGTGGCC TGGGTGCAGA GGGAGGGGAG CGTCCCCCGG GGGATCAAAA
-447 GAAAGGGAAG GGGTGCCAGG AGGGAGCCTC TCCCGGCTGG CCTCCTAGAA CTGCCCGCGC

-continued

-387 GCTCCCATCG CGACGCCCCC GCCTCTGCCA GAAACCAGCC TTCTTAGAAG GGAGGGGGGG
-327 GAAAGTGTGA ATGAGAAGTT GGGGGCGGAG CGCGCGGGGG AGGGGCCGCT GCCAGGAACG
-267 CTCGGCCAAG GCTGGCGCCG CGCCCGCCGG TCGGGCAGCC TC GCGCCGCG CT TTTGTCTCC
-207 CTCTCGGTGA GTCTCGGCGG GTCCTGGAGG CCCAGCTCC AAGCCCGCCC TCCGAGCCC
-147 CTCCCTCGCC CTCGCGCAC AGCCTTTCAG TGCAGAGTAG TGAATAACA TTACAAGAAG
-87 ACCGGCCGGG CAGTTCCAGG AATCGGGGG CGGGCGTAC TGCCGGGTA AATACCCGCG
-27 CGCGCGCCCT CCGAGGCGG TCTAACTCTG ACTCTACACT CGCCCGCTCC TACGACCGCT
+34 GTCTCTCCGG GCTCCCGGAC GCCCCCTTCC CGGCCAGCT CTCCGTCGAG GTCCCTCGCC
+94 CAGGTCCTTT GCCTGATTCG CCCAGGAGTG CGCTCATCG GCCCCGGGAG CAGCGAAGCC
+154 AGAGGGGGCG CACGCACGGG GAGCCCCTTT GTAGACTTCA CGGCTGCCAA CATCTGGGCG
+214 CAGCGCGAGC CACTGCTGGG CGCCGCCTCG CCTCGGGGAC CATAGGAGOC GCAGCCCCAA
+274 GGCCGGAGAT TTCCGCTTCGG GACTAGGTAG GAAGGAGGGG CGCGGTGTGG GGAAGGGTGG
+334 GGCATCGGT CCAGCTCGGG AGCTTTTCCC GGTTCCTCT CCCCTTCCCG GGTCAATCCC
+394 GGTAGGGAGG GGACAGGCA GGGGCGAGAG CGGATGAGAA CGAAGATCC CTGATFCCCG
+454 TCATACTCAG ACTGGGGCCC TCGGGTTTCT CTTGTCCCCT CTCTCACATA TCTCGGGTTT
+514 GGCACCCCC TTTTTTCGCC CTCGCCACTG AGGACACCG ACTGAGAGGC GCCCTGAGCG
+574 TCCCTAGGC TCTTGTTCT CTCCTCATCC TGGCCGCGCT CCTGGAGACC CAACTFCCAC
+634 GCGCGAGTTT TCTCTGGGCG TCCTCCTAGG GCGGGCAGGG GAAGAGACTG TCTGGGGTTG
+694 GCCGCGAGTG ACCGAGGACA GTCGAGTTCC GCGAGGTGGC TGGCCCTGAG ACACGGTCTA
+754 AAGCGGGCA AAGGGTGCC CCGGGCGCTA GCGGAGGCT GGAGGGCCGG GCACGCTGGA
+814 GGGTTCGGG CACTCACGCG CCTCACGCTT TGCTCTCTGC AGCTCCCCGG GATGCGGTAG
+874 CGGCCGCTGT GCGGAGGCCG CGAAGCAGCT GCAGCCACCG CCGCGCAGAT CCACGCTGGC
+934 TCCGTGCGCC ATGGTCACCC ACAGCAAGTT TCCCGCCGCC GGGATGAGCC GCCCCCTGGA
+994 CACCAGCCTG CGCCTCAAGA CCTTCAGCTC CAAAAGCGAG//

[0028] A preferred embodiment of the SOCS-3 promoter of the present invention is a DNA fragment with the sequence of nt. -2907 to +1033, inclusive (SEQ. ID. NO.:1). Other preferred embodiments of the SOCS-3 promoter include any operative fragment of SEQ. ID. NO.:1 or non-murine homologue thereof, or an operative derivative of any of these.

[0029] Preferred examples of an operative fragment include the -2759 to +104 fragment (SEQ. ID. NO.:2); the -2759 to +927 fragment (SEQ. ID. NO.:3); the -1864 to +927 fragment (SEQ. ID. NO.:4); the -857 to +927 fragment (SEQ. ID. NO.:5); the -63 to +927 fragment (SEQ. ID. NO.:6); the -97 to +927 fragment (SEQ. ID. NO.:7); the -97 to +104 fragment (SEQ. ID. NO.:8); the -87 to +927 fragment (SEQ. ID. NO.:9); the -87 to +104 fragment (SEQ. ID. NO.:10); and the -275 to +158 fragment (SEQ. ID. NO.:11). A most preferred example is the -161 to +927 fragment (SEQ. ID. NO.:12).

[0030] Non-murine homologues include any SOCS-3 promoter sequence of non-murine origin that functions in a vertebrate cell type of interest.

[0031] Another preferred embodiment of a SOCS-3 promoter is an operative derivative of SEQ. ID. NO.:1, or of any operative fragment of SEQ. ID. NO.:1 or non-murine homologue thereof, having the translational start site (the ATG in bold at nt. +944 to +946 of the murine sequence above) changed to ATT, or changed to a codon sequence, other than ATT, that is also not recognized as a translational start site; another preferred SOCS-3 promoter is a derivative of SEQ. ID. NO.:1 with the codon of the first translational start site deleted altogether. Other operative derivatives include SOCS-3 promoter sequences containing a mutation, polymorphism, or variant allele with respect to any nucleotide position of SEQ. ID. NO.:1 that does not fully eliminate promoter activity, for example, a deletion of nt. -101 to -62, or a deletion of nt. -80 to -60, or a mutation of nt. -74 to -66. The skilled practitioner is aware of suitable methods for site-directed mutagenesis, e.g., the method of Deng and Nickoloff (W. P. Deng and J. A. Nickoloff, *Analyt. Biochem.* 200:81-88 [1992]), and commercial site-directed mutagenesis kits are available, for example the Transformers site-directed mutagenesis kit (Clontech).

[0032] The murine SOCS-3 gene promoter contains a pair of STAT binding elements TT(N₃)AA, separated by 14 nucleotides, at nt. -74 to -66 and at nt. -97 to -88. In this respect, the murine SOCS-3 promoter is structurally similar to the human CIS gene promoter, which contains two functionally important pairs of STAT binding elements and is upregulated by a STAT-5 dependent pathway. (A. Yoshimura et al. [1995]; A. Matsumoto et al. [1997]; F. Verdier et al., *Mol. Cell. Biol.* 18:5852-60 [1998]). However, for activity from the present SOCS-3 promoter, only the STAT binding element at -74 to -66 is essential for optimal operability.

[0033] In a preferred embodiment, the SOCS-3 promoter is operatively linked to a DNA having a DNA sequence encoding any preselected protein or series of preselected proteins. For purposes of the present invention, "operatively linked" means that the promoter sequence, is located directly upstream from the coding sequence and that both sequences are oriented in a 5' to 3' manner, forming a transcriptional unit, such that transcription could take place in vitro in the presence of all essential enzymes, transcription factors, co-factors, activators, and reactants, under favorable physical conditions, e.g., suitable pH and temperature. This does not mean that, in any particular cell, conditions will favor transcription.

[0034] These DNA sequence encoding a preselected protein(s), or a gene-specific part, are derived from the genome of any eukaryotic organism, prokaryotic organism, or virus, and can be autologous, allogeneic, or xenogeneic with respect to the host cell. DNA sequences having a "normal" form of a gene, or a desirable allele thereof are useful in genetic therapy to compensate for endogenous production of defective protein(s) or the underexpression or overexpression of normal protein(s). In some embodiments, natural variant alleles of a gene are used, or novel genetic modification(s) are artificially induced in the DNA sequence encoding the preselected protein. Variant alleles or mutations are not limited to single nucleotide polymorphisms (SNPs), but also include deletions, insertions, inversions, translocations, transitions, transversions, or repeats. Mutations or variations are artificially induced in the DNA sequence encoding the preselected protein by a number of techniques, all of which are well known in the art. Alternatively, the DNA sequence linked to the SOCS-3 promoter encodes a gene-specific antisense RNA, such as an antisense RNA that specifically hybridizes to SOCS-3 mRNA, preventing translation therefrom. In another embodiment, the DNA sequence encodes a catalytic RNA, such as a "hairpin" or "hammerhead" ribozyme, that specifically hybridizes to a predetermined mRNA of interest and cleaves it, thereby preventing any further translation therefrom.

[0035] Most preferably, transcription of the DNA sequence from the SOCS-3 promoter results in RNA transcript that is biologically active in the cell or organism of interest, for example, as mRNA that is translated into functional protein(s); or as antisense RNA that specifically hybridizes with a functional mRNA of interest, for example a SOCS-3 mRNA, and thus prevents its translation to protein; or as catalytic RNA that specifically hybridizes with and cleaves a predetermined mRNA of interest.

[0036] In one embodiment, the preselected protein is a SOCS-3 protein, or a functional fragment thereof. Transcription

of the DNA sequence encoding the SOCS-3 protein produces mRNA transcript, which is translated into SOCS-3 protein, or a functional fragment thereof. Thus one benefit of the present invention is that the nucleic acid can be used in a genetic therapy to correct clinical disorders derived from defective negative regulation of cytokine signal transduction in GH-responsive or gp130-responsive cells. Such defective negative regulation can result from, but need not result from, endogenous underexpression of functional SOCS-3 protein, which protein inhibits in an autocrine manner the cytokine-induced Jak-STAT cascade and SOCS-3 protein synthesis itself. But an unmodulated cellular response to GH and IL-6-type cytokine signaling caused by a defect in any of various components of the cellular signal transduction mechanism can also be negatively regulated using the present nucleic acid construct containing a DNA sequence encoding a SOCS-3 protein, or a functional fragment thereof.

[0037] In another embodiment, the DNA sequence operatively linked to the SOCS-3 promoter, encodes a SOCS-3-specific nucleotide sequence, transcription of which results in the production of RNA transcript in an antisense orientation that can hybridize to SOCS-3-encoding mRNA to prevent synthesis of SOCS-3 protein. In another embodiment, SOCS-3-specific sequences are included in a DNA sequence that encodes a catalytic RNA that specifically hybridizes to SOCS-3 mRNA. These embodiments are beneficially applied to genetic therapy to correct clinical disorders derived from negative overregulation of cytokine signal transduction in GH-responsive or gp130-responsive cells.

[0038] Other preferred embodiments of the present nucleic acid construct also include, operatively linked to the SOCS-3 promoter, a DNA sequence encoding a reporter protein for facilitating the detection or selection of cells containing the present nucleic acid construct and expressing from the SOCS-3 promoter. Preferably, but not necessarily, the reporter gene encodes a fluorescent protein. Fluorescent proteins include green fluorescent protein (or enhanced green fluorescent protein), yellow fluorescent protein, blue fluorescent protein, a phycobiliprotein, such as phycoerythrin or phycocyanin, or any other protein which fluoresces under suitable wave-lengths of light. Another reporter gene suitable for some applications is a gene encoding a protein that can enzymatically lead to the emission of light from a substrate(s); for purposes of the present invention, such a protein is a "light-emitting protein." For example, a light-emitting protein includes proteins such as luciferase or apoaequorin.

[0039] The DNA of animal cells is subject to methylation at the 5' carbon position of the cytidine bases of CpG dinucleotides. Unmethylated CpGs are found preferentially in transcriptionally active chromatin. (T. Naveh-Manly et al., *Active gene sequences are undermethylated*, *Proc. Natl. Acad. Sci. USA* 78:4246-50 [1981]). Hypermethylation is associated with transcriptional repression. (R. Holliday, *The inheritance of epigenetic defects*, *Science* 238:163-70 [1987]). Since some vertebrate cell types of interest may silence expression from the present SOCS-3 promoter sequence by methylation, the skilled practitioner is aware that suitable insulator elements are employed to prevent methylation of the promoter sequence. Preferably, this is done by flanking the transcriptional unit of the promoter sequence and included gene(s) with insulator elements. For

example, by including double copies of the 1.2 kb chicken β -globin insulator element 5' to the SOCS-3 promoter sequence and 3' to the operatively linked gene(s) in the present DNA construct, methylation will be substantially prevented at CG dinucleotide sites within the SOCS-3 promoter sequence and thus expression therefrom occurs. (M. J. Pikaart et al., *Loss of transcriptional activity of a transgene is accompanied by DNA methylation and histone deacetylation and is prevented by insulators*, Genes Dev. 12:2852-62 [1998]; Chung et al., *DNA sequence which acts as a chromatin insulator element to protect expressed genes from cis-acting regulatory sequences in mammalian cells*, U.S. Pat. No. 5,610,053).

[0040] The present invention also relates to a transgenic vertebrate cell containing the nucleic acid construct of the present invention, regardless of the method by which the construct was introduced into the cell. The present cell is a growth hormone (GH)-responsive or gp130-responsive cell, for example, a cell that specifically binds any IL-6-type cytokine (i.e., binds a cytokine of the gp130 signaling subunit cytokine family). Embodiments include pituitary cells, hypothalamic cells, adrenal cells, intestinal cells, kidney cells, liver cells (e.g., hepatocytes), immune-competent cells, or bone-forming cells, such as chondrocytes. In one embodiment, the present cell is a corticotroph cell, but the cell may also be an intestinal epithelial cell a lymphocyte, a somatotroph, a lactotroph, or a gonadotroph cell. For some in vitro applications, for example with a wide variety of non-murine cells, inhibitors of histone deacetylation and DNA methylation, such as trichostatin A or sodium butyrate, can be included in the culture medium to prevent possible silencing of expression from the SOCS-3 promoter. (M. J. Pikaart et al. [1998]).

[0041] The transgenic cells of the present invention are detected, isolated or selected from non-transgenic cells with the aid of, for example, a flow-activated cell sorter (FACS), set at the appropriate wavelength(s). Alternatively, the transgenic cells are detected, isolated or selected manually from non-transgenic cells using conventional microscopic technology.

[0042] In particular applications involving a transgenic cell that expresses additional xenogeneic genes from any promoter, this expression may be linked to a reporter gene that encodes a different fluorescent or light-emitting protein from the reporter gene linked to the SOCS-3 promoter. Thus, multiple reporters fluorescing or emitting at different wavelengths can be chosen and cell selections based on the expression of multiple traits can be made.

[0043] The present invention also relates to transgenic non-human vertebrates comprising such cells, for example, non-human primates, mice, rats, rabbits, gerbils, hamsters, canines, felines or other non-human mammals. Other vertebrates include birds such as chickens, turkeys, ducks, ostriches, emus, geese, guinea fowl, doves, quail, rare and ornamental birds, and the like. Broadly speaking, a "transgenic" vertebrate is one that has had foreign DNA permanently introduced into its cells. The foreign gene(s) which (have) been introduced into the animal's cells is (are) called a "transgene(s)." The present invention is applicable to the production of transgenic vertebrates containing xenogeneic, i.e., exogenous, transgenic genetic material, or material from a different species, including biologically functional genetic

material, in its native, undisturbed form. In other embodiments, the genetic material is "allogeneic" genetic material, obtained from different strains of the same species, for example, from animals having a "normal" form of a gene, or a desirable allele thereof.

[0044] Gene delivery is by any suitable method including in vivo and in vitro gene delivery methods. (E.g., D. T. Curiel et al., U.S. Pat. Nos. 5,521,291 and 5,547,932). Typically, gene delivery involves exposing a cell to a gene delivery mixture that includes preselected genetic material together with an appropriate vector, mixed, for example, with an effective amount of lipid transfecting agent (lipofection). The amount of each component of the mixture is chosen so that gene delivery to a specific species of cell is optimized. Such optimization requires no more than routine experimentation. The ratio of DNA to lipid is broad, preferably about 1:1, although other proportions may also be utilized depending on the type of lipid agent and the DNA utilized. This proportion is not crucial. Other well known gene delivery methods include electroporation or chemical methods. (E.g., M. Ostresh, *No barriers to entry: transfection tools get biomolecules in the door*, The Scientist 13(11):21-23 (1999).

[0045] "Transfecting agent", as utilized herein, means a composition of matter added to the genetic material for enhancing the uptake of exogenous DNA segment(s) into a vertebrate cell. The enhancement is measured relative to the uptake in the absence of the transfecting agent. Examples of transfecting agents include adenovirus-transferrin-polylysine-DNA complexes. These complexes generally augment the uptake of DNA into the cell and reduce its breakdown during its passage through the cytoplasm to the nucleus of the cell.

[0046] Other preferred transfecting agents include Lipofectin®, DMRIE C, Cellfectin® or Lipofectamine (Life Technologies), LipoTAXI (Stratagene), Superfect or Effectene (Qiagen). Although these are not as efficient gene delivery (or transfecting) agents as viral transfecting agents, they have the advantage that they facilitate stable integration of xenogeneic DNA sequence into the vertebrate genome, without size restrictions commonly associated with virus-derived transfecting agents. A virus, or transfecting fragment thereof, can be used to facilitate the delivery of the genetic material into the cell. Examples of suitable viruses include adenoviruses, adeno-associated viruses, retroviruses such as human immune-deficiency virus, other lentiviruses, such as Moloney murine leukemia virus and the retrovirus vector derived from Moloney virus called vesicular-stomatitis-virus-glycoprotein (VSV-G)-Moloney murine leukemia virus, mumps virus, and transfecting fragments of any of these viruses, and other viral DNA segments that facilitate the uptake of the desired DNA segment by, and release into, the cytoplasm of cells and mixtures thereof. All of the above viruses may require modification to render them non-pathogenic or less antigenic. Other known vector systems, however, are also useful.

[0047] The present invention also relates to a method of treating a growth retardation disorder in a human subject, especially in a child or adolescent. The method involves genetically modifying a GH-responsive or gp130-responsive cell of a human subject having a growth retardation disorder, typically resulting in short stature, such as, but not limited to, dwarfism, GH deficiency, gonadal dysgenesis, chondro-

dystrophy, bone-cartilage dysplasia, or an idiopathic condition of severe short stature. Typically, the cell is a pituitary, adrenal, hypothalamic, liver, immune-competent, or bone-forming cell that is responsive to a growth-inducing cytokine in a paracrine manner. Examples include hepatocyte, lymphocyte, lymphocyte, chondrocyte, corticotroph, somatotroph, lactotroph, or gonadotroph cells, or cells derived from a pituitary tumor, adrenal tumor, hypothalamic tumor, liver tumor, or bone tumor.

[0048] The cell(s) are genetically modified by any suitable method, in vivo or in vitro, for example by transfection or transduction, using a nucleic acid construct of the present invention, comprising a SOCS-3 promoter sequence, or operative fragment thereof, operatively linked, in a transcriptional unit, to a DNA sequence encoding an RNA that specifically hybridizes to a functional SOCS-3 mRNA, i.e., a SOCS-3-specific antisense RNA. In response to the presence of a growth-inducing cytokine, in vivo, the cell transcribes, from the transcriptional unit, RNA transcript that hybridizes to SOCS-3 mRNA, preventing translation therefrom. This RNA transcript can be an antisense RNA or a catalytic RNA (ribozyme) that cleave the SOCS-3 mRNA. As a consequence, the amount of SOCS-3 protein produced within the genetically modified cell(s) is reduced relative to unmodified cells of the same kind, and one or more symptoms of the growth retardation disorder in the human subject are thereby improved, due to a lessening of SOCS-3-mediated suppression of gp130-mediated signal transduction from growth-inducing cytokines, such as GH, within the genetically modified cell(s).

[0049] The present invention also relates to a method of treating a growth acceleration disorder in a human subject. The method involves genetically modifying a GH-responsive or gp130-responsive cell from a tissue of a human subject having a growth acceleration disorder, resulting in greater than normal enlargement of one or more parts of the body, such as, but not limited to, gigantism, acromegaly, Cushing's disease, or an idiopathic condition resulting in abnormal non-edemic enlargement of bones, or facial or other soft tissue features. Typically, the cell is a pituitary, adrenal hypothalamic, liver, immune-competent or bone-forming cell that is responsive to a growth-inducing cytokine in a paracrine manner.

[0050] Examples include hepatocyte, lymphocyte, chondrocyte, corticotroph, somatotroph, lactotroph, or gonadotroph cells, or cells derived from a pituitary tumor, adrenal tumor, hypothalamic tumor, liver tumor, or bone tumor.

[0051] The cell(s) are genetically modified by any suitable method, in vivo or in vitro, for example by transfection or transduction, using a nucleic acid construct, in accordance with the present invention, comprising a SOCS-3 promoter sequence, or operative fragment thereof, operatively linked, in a transcriptional unit, to a DNA sequence encoding a SOCS-3 protein, or functional fragment thereof. In response to a growth-inducing hormone or cytokine, in vivo, SOCS-3 mRNA transcript is transcribed from the transcriptional unit, resulting in translation of SOCS-3 message to SOCS-3 protein. The amount of SOCS-3 protein produced is thereby enhanced in the genetically modified cell(s) in response to the presence of a growth-inducing cytokine, such as GH or a cytokine of the gp130 signaling subunit family, compared to the amount in unmodified cells of the same kind. The

symptom(s) of the growth acceleration disorder in the subject are thereby improved, due to increased SOCS-3-mediated cytokine signal suppression within the genetically modified cell(s). Thus, for example, in pituitary corticotroph cells, ACTH secretion is suppressed by increased levels of SOCS-3, ultimately leading to less production of glucocorticoid hormones by the adrenals and ameliorating symptoms of Cushing's disease. Similarly, the effects of excess GH, as for example in acromegaly, are moderated in accordance with the present method.

[0052] The present invention also relates to a method of treating an autoimmune disease, immune disease, or inflammatory condition in a human subject. Such diseases or conditions include, but are not limited to, Crohn's disease, ulcerative colitis, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, Grave's disease, allergic or anaphylactic reactions, or neuroendocrinological responses to psychological or physical stress. The method involves genetically modifying a cell(s) from the subject that is gp130-responsive, i.e., responsive to at least one pro-inflammatory cytokine, such as IL-6, LIF, or any other pro-inflammatory cytokine for which signal transduction is gp130-mediated. Typically, the cell is a pituitary, adrenal hypothalamic, liver, intestinal, nerve, kidney, immune-competent, or bone-forming cell that is responsive to a pro-inflammatory cytokine in a paracrine manner. Examples include hepatocyte, lymphocyte, chondrocyte, neuron, intestinal epithelial, corticotroph, somatotroph, lactotroph, or gonadotroph cells.

[0053] The cell(s) are genetically modified by any suitable method, in vivo or in vitro, for example by transfection or transduction, using a nucleic acid construct comprising a SOCS-3 promoter sequence, or an operative fragment thereof, operatively linked, in a transcriptional unit, to a DNA sequence encoding a SOCS-3 protein, or functional fragment thereof. In response to an inflammatory cytokine of the gp130 signaling subunit family, in vivo, SOCS-3 mRNA transcript is transcribed from the transcriptional unit, resulting in translation of SOCS-3 message to SOCS-3 protein. The amount of SOCS-3 protein produced is thereby enhanced in the genetically modified cell(s) in response to the presence of an inflammatory cytokine of the gp130 signaling subunit family, compared to the amount in unmodified cells of the same kind. One or more symptoms of the autoimmune disease, immune disease, or inflammatory condition in the subject are thereby improved, due to a relative increase in SOCS-3-mediated signal suppression.

[0054] In another embodiment, the nucleic acid construct that is used in the method comprises a SOCS-3 promoter sequence, or operative fragment thereof, operatively linked, in a transcriptional unit, to a DNA sequence encoding a functional anti-inflammatory cytokine of the gp130 signaling subunit cytokine family, such as IL-11, linked to a functional secretory signal. In response to the presence of a pro-inflammatory cytokine of the gp130 signaling-subunit cytokine family, in vivo, the anti-inflammatory cytokine is produced and secreted by the modified cell(s), which has both paracrine and autocrine effects that improve one or more symptoms of the autoimmune disease, immune disease, or inflammatory condition in the subject.

[0055] In some embodiments of the present methods, gene delivery is done in vitro, and the cell(s) is first obtained from

a tissue of the human subject by any suitable biopsy method, for example percutaneous biopsy, laparoscopic biopsy, or stereotactic cranial biopsy. Gene delivery is accomplished in vitro, and the genetically modified cell(s) are then re-implanted within the tissue of the human subject.

[0056] The nucleic acid construct that is used in the present methods optionally contains a reporter gene for convenient detection, isolation or selection of transgenic cells expressing from the SOCS-3 promoter as described herein. For particular applications, other DNA sequences encoding other preselected proteins are optionally linked to the SOCS-3 promoter, making their expression inducible by IL-6-type cytokines and gp130-mediated signal transduction.

[0057] The present invention also relates to a kit for genetically modifying a vertebrate cell. The kit is a ready assemblage of materials or components for facilitating the genetic modification of a vertebrate cell. The kit includes a polynucleotide comprising a murine SOCS-3 promoter sequence having SEQ. ID. NO.:1, or an operative fragment or non-murine homologue thereof, or an operative derivative of any of these, as described herein with respect to the nucleic acid construct of the present invention. Preferably the polynucleotide includes a transcriptional unit that contains the SOCS-3 promoter, operatively linked to at least one DNA sequence encoding a preselected protein or to a gene-specific part thereof, such as a SOCS-3 protein, or a functional fragment thereof, and/or a reporter gene for facilitating detection, isolation, or selection of genetically modified cells from unmodified cells. The DNA sequence encoding the preselected protein can be in a sense or antisense orientation as appropriate for a particular application. Some embodiments of the kit are configured for use in practicing the present methods of treating a growth retardation or acceleration disorder in a human subject or the present method of treating an autoimmune disease, immune disease, or inflammatory condition in a human subject.

[0058] The kit optionally contains a suitable transfecting agent, as described above. The kit includes instructions for using the materials or components effectively. The materials or components assembled in the kit are provided to the practitioner stored in any convenient and suitable way that preserves their operability and utility. For example the components can be in dissolved, dehydrated, or lyophilized form; they can be provided at room, refrigerated or frozen temperatures.

[0059] The foregoing descriptions of the nucleic acid constructs, transgenic cells, transgenic vertebrates, methods, and kits of the present invention are illustrative and by no means exhaustive. The invention will now be described in greater detail by reference to the following non-limiting examples.

EXAMPLES

Example 1

Materials and Methods

[0060] Materials. Recombinant murine LIF, IL-6, and IL-11 were purchased from R&D Systems (Minneapolis, Minn.). Mouseliver Marathon-Ready® cDNA, Advantage®-GC cDNA polymerase, mouse GenomeWalker® Kit,

and Advantage®-GC genomic polymerase were from Clontech (Palo Alto, Calif.). Maxiscript®T7 polymerase kit and ribonuclease protection kit RPA-II® were from Ambion (Austin, Tex.). Polyclonal STAT-1 p84/p91 (M-22) and STAT-3 (H-190) antibodies were from Santa Cruz Biotechnology (Santa Cruz, Calif.). Mouse genomic DNA, Erase-a Base® system, pGL3 Basic and pSV-β-galactosidase vector were from Promega (Madison, Wis.). TOPO-TA® PCR2.1 vector was from Invitrogen (Carlsbad, Calif.).

[0061] Cell Culture. Cell culture of AtT-20/D16v-F2 cells was performed as described (C. J. Auernhammer et al. [1998b]; C. J. Auernhammer et al. [1998a]). Individual clones of AtT-20 cells, overexpressing SOCS-3 (AtT-20S), mock-transfected (AtT-20M), wild type STAT-3 (AtT-20W) or dominant negative STAT-3 mutants (AtT-20 F and AtT-20D), were isolated after stable transfection. (C. J. Auernhammer et al. [1998b]; C. Bousquet & S. Melmed, J. Biol. Chem. 274:10723-30 [1998]). From each group, three separate individual clones with high stable overexpression of the respective construct were selected with G418 (1 mg/mL) for the experiments.

[0062] Northern blot analysis. Northern blot analysis was performed as described (C. J. Auernhammer et al. [1998b], C. J. Auernhammer et al. [1998a]). To detect endogenous SOCS-3 mRNA in AtT-20S cells, without hybridization to exogenous SOCS-3 mRNA derived from stable overexpression of SOCS-3, a probe spanning exon 1 and the untranslated 5' region of exon 2 as used. Otherwise, the previously described (C. J. Auernhammer et al. [1998b]; C. J. Auernhammer & S. Melmed, Endocrinology 140:1559 [1999]) murine SOCS-3 probe spanning most of the coding region of SOCS-3 was used.

[0063] 5'-Rapid Amplification of cDNA Ends (RACE) and RNase protection Assay. 5'-RACE was performed with a pre-made, adaptor-ligated Marathon-Ready® double stranded cDNA derived from pooled BALB/c mouse liver (A. Chenchik et al., Biotechnol. 3: 526-34 [1996]) and Advantage®-GC cDNA polymerase using gene-specific primary and nested antisense primers 5'-CAGTAGAATC-CGCTCTCCTGCAGCTTG-3' (SEQ. ID. NO.:15) and 5'-CTCGCTTTTGGAGCTGAAGGTCTTGAG-3' (SEQ. ID. NO.:16). Products were cloned into PCP2.1 vector, and multiple single clones sequenced.

[0064] RNase protection assay was performed with RPA-II® kit, following the manufacturer's recommendations. A fragment spanning nucleotides +158 to -275 was cloned into PCR2.1 vector; the plasmid was linearized with BamHI, and a ³²P-UTP labeled antisense probe was generated with T7 polymerase.

[0065] PCR-based characterization of the 5'-genomic region. The 5'-genomic region of SOCS-3 was cloned using a PCR-based technique (P. D. Siebert et al., Nucleic Acids Res. 23: 1087-88 [1995]) with pre-made adaptor-ligated genomic DNA fragments, derived from ICR Swiss mice, as provided by the Genomewalk® kit. PCR and subsequent nested PCR were performed by automatic hot-start as touch-down-PCR using Advantage®-GC genomic Polymerase and gene specific antisense primers 5'-CAGTAGAATC-CGCTCTCCTGCAGCTTG-3' (SEQ. ID. NO.:15) and 5'-CTCGCTTTTGGAGCTGAAGGTCTTGAG-3' (SEQ. ID. NO.:16). Further genomic walks in the 5' direction were performed with gene specific antisense primers 5'-CTTC-

CTACCTAGTCCCGAAGCGAAATC-3' (SEQ. ID. NO.:17), 5'-CAGATGTTGGCAGCCGTGAAGTCTAC-3' (SEQ. ID. NO.:18), 5'-GCGGGCGAGTGTAGAGTCA-GAGTTAGAG-3' (SEQ. ID. NO.:19), and 5'-CGATTC-TGGAAGTCCCGGCCGGTCTTC-3' (SEQ. ID. NO.:20), as well as 5'-CTCAGTGGGCTTTCTGACCTGC-CCTCTTG-3' (SEQ. ID. NO.:21) and 5'-GACTACACA-GAGTAGCTTGGGCTAGGAG-3' (SEQ. ID. NO.:22). Products were cloned into PCR2.1, and single clones were sequenced.

[0066] Different Constructs of the 5' Genomic Region of SOCS-3. 3'-Truncated forms of the full-length 3.7-kb construct in pGL3Basic vector (clone 6) were generated by PCR from genomic DNA and subsequent cloning as described above.

[0067] 5'-Truncated forms of clone 6 were generated using Erase-a-Base® kit, following the manufacturer's recommendations. Briefly, the 3.7-kb full-length construct of the 5' genomic region of SOCS-3 in pGL3Basic vector was digested with SstI and NheI, followed by unidirectional digestion with exonuclease III (S. Henikoff, Gene 28:351-59 [1984]) and subsequent re-ligation.

[0068] Mutated forms of clone 6 were generated by overlap extension PCR (A. Aiyar et al., Methods Mol. Biol. 57:177-91 [1996]) with Pfu polymerase and 5% DMSO, by using external sense primer 5'-CATCGCGACGCCCCGC-CTCT-3' (SEQ. ID. NO.:23) and antisense primer 5'-GAAACCCGAGGGCCCCAGTCTG-3' (SEQ. ID. NO.:24) with exclusive restriction sites for NruI and ApaI, respectively. Internal mutagenizing primers caused deletions of nucleotides -80 to -60 and -101 to -62, respectively. Similarly, the STAT binding element region at -74 to -66 was mutated. Gel-purified PCR-products and the original template were digested with NruI and ApaI, fragments were purified, and the mutated fragments were re-ligated into the original 3.7-kb construct in pGL3Basic vector. Each construct was verified by sequencing.

[0069] Luciferase Assay. For transient transfection experiments, 2×10^5 cells were plated in 6-well plates, incubated for 24 hours, and transfected using Lipofectamine-re and 0.5 μ g of constructs in pGL3Basic vector, and 1.0 μ g pSV- β -galactosidase. Transfected cells were first incubated for 24 hours in serum-free DMEM, followed by 6 hours of cytokine treatment and subsequent measurement of luciferase activity. In experiments comparing overexpressing dominant negative STAT-3 mutants or wild type SOCS-3, treatment with LIF was for 45 minutes.

[0070] In experiments using different promoter constructs, transfection efficiency was verified by measurement of β -galactosidase activity.

[0071] Electromobility shift assay. Nuclear extracts of AtT-20 cells and electromobility shift assay (EMSA) were performed as described (P. D. Siebert et al, Nucleic Acids Res. 23:1087-88 [1995]). Briefly, AtT-20 cells were grown to 80% confluence and were serum-deprived for 24 hours before treatment with 10^{-9} M LIF, followed by cell lysis and preparation of nuclear extracts. For the EMSA, 20- μ g nuclear extracts were preincubated for 15 minutes at room temperature in 20 μ L binding buffer (10 mM Tris-HCL 50 mM NaCl, 1 mM EDTA, 1 mM DTT, 0.1% NP40, 5% glycerol, 1 mg/mL BSA, pH 7.5) with 1 μ g of poly(dI-dC).

A 32 P-labeled double stranded oligonucleotide, corresponding to nucleotide sequence -77 to -57 of the SOCS-3 promoter (5'- 77 CAGTTCAGGAATCGGGGGGC 57 -3')(SEQ. ID. NO.:25), was used as a probe (60,000 cpm, 5 fmol per reaction) and added to each sample and binding reaction, performed at room temperature for 20 min. In competition experiments, 100-fold molar excess of unlabeled double stranded competitor oligonucleotides were added to the preincubation reaction with the double stranded oligonucleotide corresponding to nucleotide sequence -77 to -57 of the SOCS-3 promoter, this same oligonucleotide mutated at positions -74, -71, -69, and -66 (underlined) (5'- 77 CAGATCGACGATTCGGGGGGC 57 -3') (SEQ. ID. NO.:26), or the AP-2 recognition site oligonucleotide 5'-GATCGAACTGACCGCCCCGCCCGCT-3' (SEQ. ID. NO.:27). For supershift experiments 2 μ g polyclonal STAT-1 p84/p91 or STAT-3 antibody was added to the preincubation reaction and incubated for an additional 60 min at 4° C. Protein-DNA complexes were run on a 6% non-denaturing polyacrylamide gel in 0.5 \times TBE buffer (90 mM Tris, 64.6 mM boric acid, 2.5 mM EDTA), gels were dried and autoradiographs were exposed (Kodak biomax MS film at -70° C.).

[0072] Statistical analysis. Statistical analysis was performed by unpaired I-test. All values are mean \pm SEM.

Example 2

5'-Genomic Sequence of Murine SOCS-3 and Determination of the Transcription Start Site by 5'-RACE and RNase Protection Assay.

[0073] Based on the sequence information from the 5' genome walk, a full length 5' product of murine SOCS-3 spanning ~3.8-kb of genomic sequence was generated from ICR Swiss mice genomic DNA by PCR with Advantage®-GC genomic polymerase using the following sense and antisense primers: 5'-GACGTTCCCTAAAAGCATGCAT-GTCAACCAG-3' a (SEQ. ID. NO.:28) and 5'-GGATCT-GCGCGGGGTGGCTGCAGCTGCTT-3' (SEQ. ID. NO.:29). Cloning of the product into PCR2.1 vector was followed by verification of sense orientation, sequencing, restriction enzyme digestion with SstI and XhoI, and sub-cloning of a -3.7-kb construct into pGL3Basic vector (clone 6). Sequence information was obtained for the whole 3.8 kb. (SEQ. ID. NO.:1).

[0074] 5'-RACE revealed the existence of an untranslated exon 1 (+1 to +289), separated from exon 2 (starting at +854) by an intron (+290 to +853). Using RNase protection assay, the main transcription start site was defined and is referred to as +1. The previously determined translation initiation site for murine SOCS-3 (GenBank Accession U88328) (R. Starr et al., Nature 387:917-21 [1997]) was in exon 2 at +944.

Example 3

Effects of Different Cytokines on SOCS-3 Promoter Activity and Gene Expression

[0075] FIG. 1 shows the stimulatory effect of various cytokines on expression from the SOCS-3 promoter sequence. AtT-20 cells were either untreated, or stimulated with 0.5×10^{-9} M LIF, IL-6, or IL-11 for 60 or 120 min.

Northern blot analysis showed a SOCS-3-specific signal of uniform transcript size of -2.8 kb (**FIG. 1A**).

[0076] LIF was the most potent inducer of SOCS-3 mRNA expression. Although IL-6 and IL-11 were less potent stimuli of SOCS-3 gene expression, they each showed a similar pattern of SOCS-3 mRNA induction. (**FIG. 1A**).

[0077] For measurement of SOCS-3 promoter activity, transient transfections of AtT-20 cells were performed either with pGL3Basic alone or with clone 6, a construct containing nucleotides $-2,759$ to $+927$ of the 5'-genomic region of murine SOCS-3 linked to the luciferase reporter gene in pGL3Basic vector. (**FIG. 1B**). Relative SOCS-3 promoter activity is indicated by relative light unit values in **FIG. 1B**, calculated from 4 independently performed experiments. Each experiment was performed with $n=3$ wells per group. Asterisks indicate in-group significance of untreated (-) vs. treated (+); *, $P<0.05$; **, $P<0.01$. AtT-20 cells transfected with clone 6 showed a significantly higher basal luciferase activity than cells transfected with pGL3Basic alone (4043 ± 443 vs. 1611 ± 398 relative light units [RLU]; $P<0.001$). Stimulation with 0.5×10^{-9} M LIF, IL-6, or IL-11 caused no further increase of luciferase activity in control AtT-20 cells transfected with pGL3Basic alone. However, in comparison to untreated cells, AtT-20 cells transfected with clone 6 showed an approximately 10-fold ($P<0.01$) increase in luciferase activity following stimulation with LIF, a 2-fold (not significant) increase following stimulation with [L-6, and a 3-fold ($P<0.05$) stimulation of luciferase activity by IL-11. (**FIG. 1B**).

[0078] Activation by LIF, IL-6 and IL-11, of SOCS-3 promoter activity and gene expression thus is concordant with our finding of a functionally important STAT-1/STAT-3 binding element in the murine SOCS-3 promoter region.

Example 4

Effect of Overexpressed Dominant Negative STAT-3 Mutants or Wild Type SOCS-3 on LIF-Induced SOCS-3 Gene Expression and Promoter Activity

[0079] Expression from the SOCS-3 promoter is partly dependent both on the expression of STAT-3 and SOCS-3 itself **FIG. 2** shows the effect of overexpressed dominant negative STAT-3 mutant or wild type SOCS-3 on LIF-induced SOCS-3 gene expression and promoter activity in AtT-20 cells. AtT-20 cells overexpressing wild type STAT-3 (AtT-20W) showed a 5.4 ± 0.7 -fold increase of SOCS-3 mRNA levels after stimulation with 0.5×10^{-9} M LIF for 45 min. In comparison, AtT-20 cells overexpressing the dominant negative mutants STAT-3F (AtT-20F) and STAT-3D (AtT-20D) both showed relatively diminished induction of SOCS-3 mRNA after stimulation with LIF: 3.4 ± 0.4 ($p=0.07$) and 2.6 ± 0.1 -fold ($p<0.02$), respectively. (**FIG. 2A, 2B**). Similarly, transient transfection experiments with clone 6 showed stimulation of luciferase activity by LIF (6.9 ± 0.5 -fold) in AtT-20W cells, but only 5.4 ± 0.5 -($P=0.09$) and 3.4 ± 0.4 -fold ($P<0.01$) stimulation were observed in AtT-20F and AtT-20D cells, respectively. (**FIG. 2C**). These results, showing that LIF-induced SOCS-3 promoter activity and gene expression is decreased in these dominant negative STAT-3 mutant transfectants, indicate that SOCS-3 promoter activity is at least partly dependent on wild type STAT-3 expression. (**FIG. 2A-C**).

[0080] Overexpression of wild type SOCS-3 in AtT-20 cells abrogated LIF-induced SOCS-3 promoter activity and gene expression. (**FIG. 2D-F**). Mock-transfected AtT-20 cells (AtT-20M) showed an approximately 5-fold increase of SOCS-3 mRNA levels after 45 min stimulation with 0.5×10^{-9} M LIF, while AtT-20 cells overexpressing wild type SOCS-3 (AtT-20S), showed a significant inhibition of LIF-induced SOCS-3 mRNA expression. (**FIG. 2D, 2E**). Similarly, transient transfection experiments with clone 6 revealed luciferase activity to be stimulated by LIF (9.9 ± 1.3 -fold) in AtT-20M cells, while LIF-induced luciferase activity in AtT-20S cells was abrogated and did not differ substantially from luciferase activity in untreated AtT-20S cells. (**FIG. 2F**). These results indicate a negative autoregulatory feedback of SOCS-3 on its own cytokine-induced gene expression.

[0081] LIF-induced SOCS-3 mRNA and luciferase activity were each calculated from 3 independently performed experiments. Each experiment was performed with 3 different clones per group. LIF-induced luciferase activity was normalized to the untreated control for each clone.

Example 5

Functional Analysis of Different SOCS-3 5' Region-Luciferase Constructs

[0082] Clone 6 is the -2757 to $+929$ 5' genomic region of murine SOCS-3 linked to the luciferase reporter in pGL3Basic vector. 3'-Truncations of clone 6 were: clone 4 (nt. -2759 to $+104$) and clone 2 (nt. -2759 to -716). 5'-Truncations of clone 6 were: clone 6T1 (nt. -1864 to $+927$); clone 6T2 (nt. -857 to $+927$); clone 6T3 (nt. -152 to $+927$); and clone 6T4 (nt. -63 to $+927$). Analysis of clone 6 sequence with Mat Inspector V2.2 (K. Quandt et al., Nucleic Acids Res. 23: 4878-84 [1995]), revealed potential STAT binding sites containing the consensus binding sequence $TT(N)_3AA$ (C. M. Horvath et al., Genes Dev. 9:984-94 [1995]; J. E. Darnell, Jr., Science 277:1630-35 [1997]; S. Becker et al., Nature 394:145-51 (1998)) located at nt. -97 to -89 and nt. -74 to -66 , as well as at nt. -347 to -339 and -1403 to -1395 . However, only the STAT binding site from nt. -74 to -66 showed the more specific sequence TTC-CAGGAA, indicating a potential binding site for STAT-1 and STAT-3.

[0083] Therefore, in subsequent experiments, the focus centered on the STAT binding site at nt. -74 to -66 , constituting part of the tandem STAT binding region pair of nt. -97 to -89 and nt. -74 to -66 . Using overlap extension PCR, we deleted the complete tandem STAT binding region from nt. -101 to -62 (clone 6D2), or only the 3'-located STAT binding element from nt. -80 to -60 (clone 6D1). In clone 6M1, the 3'-located STAT binding element from nt. -74 to -66 was not deleted, but mutated to ATCGACGAT, thus destroying the specific binding sequence TTC-CAGGAA (SEQ. ID. NO.:13). Clone 8 was a minimal -275 to 158 5' genomic region of SOCS-3 linked to the luciferase reporter in pGL3Basic vector. Basal and LIF-induced luciferase activity were assayed after transient transfection of corticotroph AtT-20 cells with the different constructs.

[0084] **FIG. 3** shows relative luciferase activities in transfected AtT-20 cells bearing the different constructs. Relative luciferase activities were calculated in comparison to basal

-continued

<221> NAME/KEY: promoter
 <222> LOCATION: (0)...(0)

<400> SEQUENCE: 1

```

gacgttccta aaagcatgca tgtcaccag cttaccacc catctcaggc cacagcagcc    60
tgagagagcg gaagaacacc tgctggctct gtcccacctc tcctcttcaa acagccccac    120
atcctccagt ttgtctctgg gtggagctcc ctgctggccc tgcagaggga aggctctcct    180
aagcatcatc tadcagaacg tcttcaaaaa aaaaaaaaaa aaaaaaaag cctctccagc    240
caggctagct ctaacaccat ttcttcccct tcccctctct caaattcact tatctttttt    300
tttttttttt tttttggatt tttgagacag ggtttctctg tatagccctg gttgtcctgg    360
aactcacttt gtacaccagc ctggcctcga actcagagat ccacctgect ctgcctctctg    420
agtgtctggga ttaaaggcgt gcgccaccac gcccggttaa attcacttat ctatttaatg    480
tatatagggg ataggctgcc ctgaaactca caaagatctg cttgctttgc ttctggaata    540
ctaaagggtg gtgctaccat cacagggacc aagatttatt ttaattctgt atatgtgtgt    600
gtgtgtgtgt gtgtatgggg ggtgcacatg agtacagatt cccttgaggg cctgggggtg    660
cttaggactg gggttacaac agttgtgacc catcctacat aggtcctggc accaacaccc    720
ccccccccc ccccgctctt ccagaagtgc agcagggtgtt cttactgct gagccagcaa    780
tccagcccc gacttcccct tcttacttaa gaagctatca cagtgtctca ctgggtcaca    840
atcatgacta gtccctgtct atggcccaca gcctcttccc cactgtgggt tttgccccgc    900
agctctgccg cccagcgctg gcaccogagg cctgacagag ccaggcacga agtcagggtt    960
tgtggaatgg atgaatgaac ttgactcgtg gcagagcatt gtaatttaca aagcactttc   1020
ccatccatta actccagggc tatttcttaa gagtctctcc tgcctccac tgcctcggc   1080
tcagaggcat acggccaagg cagtggctgg ggaacactcc ctgaatgaga tcaaggaggg   1140
cttgttcaca gagaaagga gaatccattt ggggagcctg agagtgactc gaaggcaagg   1200
actgggcctc acctgtggga tctccatctg tgagcatccg ctcatcagac cagtgtgaga   1260
tattttaaat aagggcccta agcctcttga ctactggaat tgccaggggc gggggacaga   1320
tgggcaccca tccctattta acagataaca agactgagtc cagagaggca gtgcacctgc   1380
cctgtctct cttagtctct cagcatcagt ggagcagatt ggacacagtg gcccagaagg   1440
gaagcaggca gccctccctc ctagcccaag ctactctgtg tagtcagttt gccctcctac   1500
tgggtttaca agaagcctgt ggtatccaag agggcaggtc agaaagcca ctgagagcag   1560
acactgtgtg tcaacttagct ggttctcagg tggctgccac ttctgtctgc ctgttgcaaa   1620
actogacact aggcctttat agatactcac gtgaccagga gtaacaacc tttcacctca   1680
atcacctgct cttatcaata ctcccctctc accccacatc cgggaaagt cagacacctt   1740
aaaaagttag ggcaagagag ggtccattct gacacctcag cgactttcag gcagtggctg   1800
aaccctttac aacgctctgt ggacagctct cctagtcgac attccttctc aggtttgacc   1860
ctgtcctggg aagtgaggct tctctctctg ggttcccac tcctgttctt gaataaggag   1920
ccccacaacc tcttattctc tctatacaga gcttgggaaa cagcaaaact cggctcgcct   1980
acaagactcc agcgcgccct ctggtggact cgggggacga gcatgggatg agggtttctt   2040
tcctctagct cccccaccgc gccgagagta cctgggcgga ccacacagtc gccacgcagg   2100
ttgggaggcc cagatgagtg ataaggtagt agttagctgc tcctcccacc ccactcccca   2160

```

-continued

```

aaggacatca gcacccacgt ctgtcaccga agaaccaggc aatgggcgga tgagctgagg 2220
ccaggtagct gcttctaagt cagtgtctcc tccacttctg gatctcacag ctctcatctt 2280
tgacacctgtc tacaggtaaa tgtcgcgcat cccctcctc cacttcctag gtccccagtg 2340
ggctggtggc tgaatggtcc tacgtccctt ttggttgga cgggatgctt ggaactgtac 2400
atgaggacct cggggtggcc tgggtgcaga gggaggggag cgtccccgcg gggatcaaaa 2460
gaaaggaag ggggtccagg agggagcctc tcccggctgg cctcctagaa ctgcccgcgc 2520
gtcccacatg cgacgcccc gcctctgcca gaaaccagcc ttcttagaag ggaggggggg 2580
gaaagtgtga atgagaagtt gggggcggag cgcgcggggg aggggcccgt gccaggaaacg 2640
ctcggccaag gctggcgcgc cgcgcgcgcg tcgggcagcc tcgcgcgcgc ctttgtctcc 2700
ctctcggtag gtctcggcgg gtccctggagg cccagctcc aagcccgcgc tccgcagccc 2760
ctcctcgcgc ctccgcgcac agcctttcag tgcagagtag tgactaaaca ttacaagaag 2820
accggccggg cagttccagg aatcgggggg cggggcgtac tggccgggta aataccgcgc 2880
cgcgcggcct ccgagggcgc tctaactctg actctacact cgcccgcctc tacgaccgct 2940
gtctctccgg gctcccggac gccccctcc cggcccagct ctccgtcagag gtccctcgc 3000
caggtccttt gcctgattcg cccaggagtg cgcctcatcg gcccggggag cagcgaagcc 3060
agagggggcg cacgcacggg gagccccttt gtagacttca cggctgcaa catctggggc 3120
cagcgcgagc cactgctggg cgcgcctcg cctcggggac cataggaggc gcagcccaa 3180
ggccggagat ttcgcttcgg gactaggtag gaaggagggg cgcggtgtgg ggaagggtgg 3240
gggcatcggt ccagctcggg agcttttccc ggtttctcct ccccttccc ggtcattccc 3300
ggtaggggag ggacgaggca gggggcagag cggatgagaa ccgaagatcc ctgattccc 3360
tcatactcag actggggccc tcggggttct cctgtcccct ctctcacata tctcggggtt 3420
ggcacccccc ttttttcgcc ctgcaccatg aggacaccgg actgagaggc gccctgagcg 3480
tcccagggc tcttgtgtct ctcccaccc tggccgcgct cctggagacc caacttccac 3540
gcgcgagttt tctctgggc tcctcctag ggcggcaggg gaagagactg tctggggttg 3600
gccggcagtg accgaggaca gtcgagttcc gcgaggtggc tgggcctgag acacgggtcta 3660
aagcggggca aaggggtgcc ccgggcgcta ggcggaggct ggagggcccg gcaocgtgga 3720
gggttccggg cactcacgcg cctcacgctt tgctctctgc agctcccgcg gatgcggtag 3780
cggccgctgt gcggagggcg cgaagcagct gcagccaccg ccgcgcagat ccacgctggc 3840
tccgtgcgcc atggtcacc acagcaagtt tcccgcgcgc gggatgagcc gcccccgtga 3900
caccagcctg cgctcaaga ccttcagctc caaaagcgag 3940

```

```

<210> SEQ ID NO 2
<211> LENGTH: 2863
<212> TYPE: DNA
<213> ORGANISM: MURINE
<220> FEATURE:
<221> NAME/KEY: promoter
<222> LOCATION: (-2759)...(104)

```

```

<400> SEQUENCE: 2

```

```

ccctgctggc cctgcagagg gaaggctctc ctaagcatca tctatcagaa cgtcttcaaa 60
aaaaaaaaa aaaaaaaaaa agcctctcca gccaggctag ctctaacc acc atttcttccc 120

```

-continued

cttccctct ctcaaattca cttatctttt tttttttttt tttttttgga tttttgagac	180
agggtttctc tgtatagccc tggttgtcct ggaactcact ttgtacacca gcctggcctc	240
gaactcagag atcccactgc ctctgcctcc tgagtgtgg gattaaaggc gtgcgccacc	300
acgccccgct aaattcactt atctatttaa tgtatatagg gtataggctg cccttgaact	360
cacaaagatc tgcttgcttt gcttctgaa tactaaagggt gtgtgctacc atcacaggga	420
ccaagattta ttttaattct gtatatgtgt gtgtgtgtgt gtgtgtatgg ggggtgcaca	480
tgagtacaga ttcccttgga ggccctgggt ggcttaggac tggggttaca acagttgtga	540
cccatcctac ataggctctg gcaccaacac ccccccccc ccccccgtc ttccagaagt	600
gcagcaggtg ttcttaactg ctgagccagc aatccagccc ctgacttccc tctcttactt	660
aagaagctat cacagtgtct cactgggtca caatcatgac tagtccttgc tcatggccca	720
cagcctcttc cccactgtgg gttttgcccc gcagctctgc cggcccagcg ctgcaccga	780
ggcctgacag agccaggcac gaagtcaggg tttgtggaat ggatgaatga acttgactcg	840
tggcagagca ttgtaattta caaagcactt tcccatccat taactccagg gctatcttct	900
aagagtctc cctgtctccc actgcctctg gctcagaggc atacggtcaa ggcagtggtc	960
ggggaacct ccctgaatga gatcaaggag ggcttgttca cagagaaagg gagaatccat	1020
ttggggagcc tgagagtgc tcgaaggcaa ggactgggcc tcacctgtgg gatctccatc	1080
tgtgagcatc cgctcatcag accagtgtga gatattttaa ataaggcccc taagcctctt	1140
gactactgga attgccaggg gcgggggaca gatgggcacc catccctatt taacagataa	1200
caagactgag tccagagagg cagtgcacct gccctggtct ctcttagttc ctcagcatca	1260
gtggagcaga ttggacacag tgggccagaa gggaaagcagg cagccctccc tcctagccca	1320
agctactctg ttagtcagtt tgccctcct actggtgtta caagaagcct gtggtatcca	1380
agagggcagg tcagaaagcc cactgagagc agacactgtg tgtcacttag ctggttctca	1440
ggtggctgcc acttcctgct gcctgttgca aaactcgaca ctaggccttt atagatactc	1500
acgtgaccag gagtaaaaaa cctttcacct caatcacctg ctcttatcaa tactccctct	1560
ccacccacc atcgggaaaag ttcagacacc ttaaacgta gaggcaagag agggctccatt	1620
ctgacacctc agcactttc aggcagtggc tgaaccggtt acaacgctct gtggacagtc	1680
ctcctagtgc acattccttc tcaggtttga ccctgtctg ggaagtgagg cttctctctc	1740
tgggttcccc actcctgttc ttgaataagg agccccaaa cctcttattc tctctataca	1800
gagcctggga aacagcaaaa ctcggtctgc ctacaagact ccagcgcgcc ctctggtgga	1860
ctcgggggac gagcatggga tgagggtttc tttcctctag ctccccacc gcgccgagag	1920
tacctgggag gaccacagtt tcgccacgca ggttgggagg cccagatgag tgataaggta	1980
gtagttagct gtcctccca cccactccc caaaggacat cagcaccac gtctgtcacc	2040
gaagaaccag gcaatgggag gatgagctga ggccaggtag ctgcttctaa gtcagtgtct	2100
cctcacttc tggatctcac agcttcatct tttggacctg tctacaggta aatgtcgcgc	2160
atccccctcc tccacttctt aggtccccag tgggctggtg gctgaatggt cctacgtccc	2220
ttttggttg cacgggatgc ttggaactgt acatgaggac ctggggtgg cctgggtgca	2280
gagggagggg agcgtccccg cggggatcaa aagaagggga aggggtgcca ggagggagcc	2340
tctccccgct ggccctctag aactgccccg gcgctcccat cgcgacgccc ccgctctgc	2400

-continued

```

cagaaaccag ccttcttaga agggaggggg gggaaagtgt gaatgagaag ttggggggcg 2460
agcgcgcggg ggagggggccg ctgccagaa cgctcggcca aggctggcgc cgcgcccgcc 2520
ggtcgggcag cctcgcgcgc cgtttgtct ccctctcggg gactctcggc gggctctgga 2580
ggccccagct ccaagcccgc cctccgcagc ccctccctcg ccctccgcgc acagcctttc 2640
agtgcagagt agtgactaaa cattacaaga agaccggccg ggcagttcca ggaatcgggg 2700
ggcggggcgt actggccggg taaataccg cgcgcgcggc ctccgaggcg gctctaactc 2760
tgactctaca ctgcgccgct cctacgaccg ctgtctctcc gggctcccgg acgccccctt 2820
cccggcccag ctctccgctc aggtccctcg cccaggctct ttg 2863

```

```

<210> SEQ ID NO 3
<211> LENGTH: 3686
<212> TYPE: DNA
<213> ORGANISM: MURINE
<220> FEATURE:
<221> NAME/KEY: promoter
<222> LOCATION: (-2759)...(927)

```

```

<400> SEQUENCE: 3

```

```

ccctgctggc cctgcagagg gaaggctctc ctaagcatca tctatcagaa cgtcttcaaa 60
aaaaaaaaaa aaaaaaaaaa agcctctcca gccaggctag ctctaaccacc atttcttccc 120
cttcccctct ctcaaattca cttatctttt tttttttttt tttttttgga tttttgagac 180
agggtttctc tgtatagccc tgggtgtcct ggaactcact ttgtacacca gcctggcctc 240
gaaactcagag atccacctgc ctctgcctcc tgagtgtctg gattaaaggc gtgcgccacc 300
acgcccggct aaattcactt atctatttaa tgtatatagg gtataggctg cccttgaact 360
cacaaagatc tgcttctttt gcttctggaa tactaaaggc gtgtgtctacc atcacaggga 420
ccaagattta ttttaattct gtatatgtgt gtgtgtgtgt gtgtgtatgg ggggtgcaca 480
tgagtacaga ttcccttgga gccctggggg ggcttaggac tggggttaca acagttgtga 540
cccctctac ataggtcctg gcaccaacac cccccccccc cccccccgtc ttccagaagt 600
gcagcaggty ttcttaactg ctgagccagc aatccagccc ctgacttccc tctcttactt 660
aagaagctat cacagtgtct cactgggtca caatcatgac tagtccttgc tcatggccca 720
cagcctcttc cccactgtgg gttttgcccc gcagctctgc cgcgccagcg ctgcaccgga 780
ggcctgacag agccaggcac gaagtcaggg tttgtggaat ggtggaatga acttgactcg 840
tggcagagca ttgtaattta caaagcactt tcccatccat taactccagg gctatttcct 900
aagatcctc cctgtcctcc actgcctcgc gctcagaggc atacggtcaa ggcagtggct 960
ggggaacact ccctgaatga gatcaaggag ggcttgttca cagagaaagg gagaatccat 1020
ttggggagcc tgagagtgc tcgaaggcaa ggactgggcc tcacctgtgg gatctccatc 1080
tgtgagcatc cgctcatcag accagtgtga gatattttaa ataaggcccc taagcctctt 1140
gactactgga attgccaggg gcgggggaca gatgggcacc catccctatt taacagataa 1200
caagactgag tccagagagg cagtgcacct gccctggtct ctcttagttc ctccagatca 1260
gtggagcaga ttggacacag tgggcccagaa ggaagcagg cagccctccc tcctagccca 1320
agctactctg tgtagtctgt ttgccctcct actggtgtta caagaagcct gtggtatcca 1380
agagggcagg tcagaaagcc cactgagagc agacactgtg tgtcacttag ctggttctca 1440
ggtgctgccc acttctgctg gcctgttgca aaactcgaca ctaggccttt atagatactc 1500

```

-continued

acgtgaccag	gagtaaaca	cctttcacct	caatcacctg	ctcttatcaa	tactccctct	1560
ccaccccacc	atcgggaaa	ttcagacacc	ttaaacgta	gaggcaagag	aggggccatt	1620
ctgacacctc	agcgactttc	aggcagtggc	tgaacccgtt	acaacgctct	gtggacagtc	1680
ctcctagteg	acattccttc	tcaggtttga	ccctgtcctg	ggaagtgagg	cttctctctc	1740
tgggttcccc	actcctgttc	ttgaataaag	agccccacaa	cctcttattc	tctctataca	1800
gagcctggga	aacagcaaaa	ctcggctcgc	ctacaagact	ccagcgcgcc	ctctggtgga	1860
ctcgggggac	gagcatggga	tgagggttct	tttctcttag	ctccccacc	gcgccgagag	1920
tacctgggag	gaccacagct	tcgccacgca	ggttgggagg	cccagatgag	tgataaggta	1980
gtagttagct	gctcctccca	ccccactccc	caaaggacat	cagcaccac	gtctgtcacc	2040
gaagaaccag	gcaatgggag	gatgagctga	ggccaggtag	ctgcttctaa	gtcagtgctt	2100
cctccacttc	tgatctcac	agcttcatct	tttggacctg	tctacaggta	aatgtcgcgc	2160
atccccctcc	tccacttctc	aggtccccag	tgggctgggtg	gctgaatggt	cctacgtccc	2220
ttttggttgg	cacgggatgc	ttggaactgt	acatgaggac	ctcggggtgg	cctgggtgca	2280
gagggagggg	agcgtccccg	cgggatcaaa	aagaaagggg	aggggtgcca	ggagggagcc	2340
tctccccgct	ggcctcctag	aactgccccg	gcgctcccat	cgcgacgcc	ccgctctg	2400
cagaaaccag	ccttcttaga	agggaggggg	gggaaagtgt	gaatgagaag	ttggggcg	2460
agcgcgcggg	ggagggcgcc	ctgccaggaa	cgctcggcca	aggctggcgc	cgcgccgcc	2520
ggtcgggcag	cctcgcgcgc	cgctttgtct	ccctctcggg	gagtctcggc	gggtcctgga	2580
ggccccagct	ccaagccccg	cctccgcagc	ccctccctcg	ccctccgcgc	acagcctttc	2640
agtgcagagt	agtactaaa	cattacaaga	agaccggccg	ggcagttcca	ggaatcgggg	2700
ggcggggcgt	actggccggg	taaatacccc	cgcgcgcggc	ctccgagggc	gctctaactc	2760
tgactctaca	ctcgcgccct	cctacgaccg	ctgtctctcc	gggctcccgg	acgccccctt	2820
ccccggccag	ctctccgtcg	aggtccctcg	cccaggtcct	ttgctgatt	cgcccaggag	2880
tgccctcat	cggccccggg	agcagcgaag	ccagaggggg	cgcacgcacg	gggagcccct	2940
ttgtagactt	cacgggtgcc	aacatctggg	cgcagcgcga	gccactgctg	ggcggccct	3000
cgcctcgggg	accataggag	gcgcagcccc	aaggccggag	atttcgcttc	gggactaggt	3060
aggaaggagg	ggcgcggtgt	ggggaagggt	gggggcctcg	gtccagctcg	ggagcttttc	3120
ccggtttctc	ctccccctcc	cgggtcattc	ccggtaggga	ggggacgagg	cagggggcag	3180
agcggatgag	aaccgaagat	ccctgattcc	cgtcatactc	agactggggc	cctcgggttt	3240
ctcctgtccc	ctctctcaca	tatctcgggt	ttggcaccoc	cctttttctg	ccctcgcac	3300
tgaggacacc	ggactgagag	gcgccttag	cgtccctagg	gctcttgtgt	ctctccccat	3360
cctggccgcg	ctcctggaga	cccaactccc	acgcgcgagt	tttctctggg	cgctctccta	3420
gggcgggcag	gggaagagac	tgtctggggt	tggccggcag	tgaccgagga	cagtcgagtt	3480
ccgcgaggtg	gctgggctcg	agacacggtc	taaagcgggg	caaaggggtg	ccccgggcgc	3540
tagggggagg	ctggagggcc	gggcaogctg	gagggttccg	ggcactcacg	cgcctcacgc	3600
tttgctctct	gcagctcccc	gggatgcggt	agcggccgct	gtcgggaggc	cgcgaagcag	3660
ctgcagccac	cgcgcgcgag	atccac				3686

-continued

```

<210> SEQ ID NO 4
<211> LENGTH: 2791
<212> TYPE: DNA
<213> ORGANISM: MURINE
<220> FEATURE:
<221> NAME/KEY: promoter
<222> LOCATION: (-1864)...(927)

<400> SEQUENCE: 4

ttcctaagag tctccctgt cctccactgc cctcggctca gaggcatacg gtcaaggcag    60
tggctgggga aactccctg aatgagatca aggagggctt gttcacagag aaagggagaa   120
tccatttggg gagcctgaga gtgactcga ggcaaggact gggcctcacc tgtgggatct   180
ccatctgtga gcatccgctc atcagaccag tgtgagatat tttaaataag gccccaagc   240
ctcttgacta ctggaattgc cagggggcgg ggacagatgg gcacccatcc ctatttaaca   300
gataacaaga ctgagtcag agaggcagtg cacctgcctt ggtctctctt agttcctcag   360
catcagtgga gcagattgga cacagtgggc cagaaggaa gcaggcagcc ctccctccta   420
gccccagcta ctctgtgtag tcagtttgcc ctccactagg tgttacaaga agcctgtggt   480
atccaagagg gcaggtcaga aagcccactg agagcagaca ctgtgtgtca cttagctggt   540
tctcaggtgg ctgccacttc ctgctgcctg ttgcaaaact cgacactagg cctttataga   600
tactcacgtg accaggagta aacaaccttt cacctcaatc acctgctctt atcaatactc   660
cctctccacc ccaccatcgg gaaagtccag acaccttaa acgtagaggc aagagagggg   720
ccattctgac acctcagcga ctttcaggca gtggctgaac ccgttacaac gctctgtgga   780
cagtcctcct agtcgacatt ccttctcagg tttgaccctg tcctgggaag tgaggcttct   840
ctctctgggt tccccactcc tgttctttaa taaggagccc cacaacctct tattctctct   900
atacagagcc tgggaaacag caaaactcgg ctgcctaca agactccagc ggcacctctg   960
gtggactcgg gggacagaca tgggatgagg gtttctttcc tctagctccc ccaccgcgcc  1020
gagagtacct gggcggacc acagttcgc acgcaggttg ggaggcccag atgagtgata  1080
aggtagtagt tagctgctcc tcccaccca ctccccaaag gacatcagca cccacgtctg  1140
tcaccaaga accaggcaat gggcggatga gctgaggcca ggtagctgct tctaagtcag  1200
tgtctcctcc acttctggat ctcacagctt catcttttgg acctgtctac aggtaaatgt  1260
cgcgcacccc cctcctccac ttcctaggtc cccagtgggc tgggtggctga atggtcctac  1320
gtcccttttg gttggcacgg gatgcttggg actgtacatg aggacctcg ggtggcctgg  1380
gtgcagaggg aggggagcgt ccccgcgggg atcaaaagaa agggaagggg tgccaggagg  1440
gagcctctcc cggctggcct ctagaactg cccgcgcgct cccatcgcga cgcctccgcc  1500
tctgccagaa accagccttc ttagaagggg ggggggggaa agtgtgaatg agaagtggg  1560
ggcggagcgc gcgggggagg ggcgctgccc agaacgctc ggccaaggct ggcgcccgc  1620
ccgcggctgc ggcagcctcg cgcgcgctt tgtctccctc tcggtgagtc tcggcgggct  1680
ctggaggccc cagctccaag cccgcctccc gcagcccctc cctcgcctc cgcgcacagc  1740
ctttcagtg agagtagtga ctaaacatta caagaagacc ggccgggagc ttcagggaat  1800
cggggggcgg ggcgtactgg cgggtaaat acccgcgcgc ggcgcctcc aggcggctct  1860
aactctgact ctacactcgc ccgctcctac gaccgctgtc tctccgggct cccggacgcc  1920
cccttcccgg ccagctctc cgtcaggtc cctcggcccag gtcctttgcc tgattcggcc  1980

```

-continued

```

aggagtgcgc ctcatcgccc cggggagcag cgaagccaga gggggcgcac gcacggggag 2040
cccccttcta gacttcacgg ctgccaacat ctgggcgcag cgcgagccac tgctggggcg 2100
cgctcgcct cggggaccat aggagggcga gcccacaaggc cggagatttc gcttcggggac 2160
taggtagtaa ggagggggcg ggtgtgggga aggtgtgggg catcgggtcca gctcggggagc 2220
ttttcccggt ttctcctccc cttcccgggt cattcccgggt agggagggga cgaggcaggg 2280
ggcagagcgg atgagaaccg aagatcccctg attcccgtca tactcagact ggggcacctg 2340
ggtttctcct gtcccctctc tcacatatct cgggtttggc accccccttt ttctgcccctc 2400
gccactgagg acaccggact gagagggccc ctgagcgtcc ctagggtctt tgtgtctctc 2460
cccactctgg ccgcgctcct ggagacccaa cttccacgcg cgagttttct ctgggcgtcc 2520
tcctagggcg gccaggggaa gagactgtct ggggttgccc gccagtgacc gaggacagtc 2580
gagttccgcg aggtggtcgg gcctgagaca cggctctaaag cggggcaaag ggtgccccg 2640
ggcgctaggg ggaggtgga gggccgggca cgtgggaggg ttccgggcac tcacgcgcct 2700
cacgctttgc tctctcgcgc tccccgggat gcggtagcgg ccgctgtgcg gaggccgcga 2760
agcagctgca gccaccgccc cgcagatcca c 2791

```

```

<210> SEQ ID NO 5
<211> LENGTH: 1803
<212> TYPE: DNA
<213> ORGANISM: MURINE
<220> FEATURE:
<221> NAME/KEY: promoter
<222> LOCATION: (-857)...(927)

```

```

<400> SEQUENCE: 5
gggtttcttt cctctagctc ccccaccgcg ccgagagtac ctggggcggac ccacagttcg 60
ccacgcaggt tgggagggccc agatgagtga taaggtagta gttagctgct cctcccaccc 120
cactcccaca aggacatcag ccccacgctc tgtcaccgaa gaaccaggca atgggcggat 180
gagctgaggc caggtagctg cttctaaatc agtgtctcct ccacttctgg atctcacagc 240
ttcatctttt ggacctgtct acaggtaaat gtcgcgcac cccctcctcc acttcctagg 300
tcccagtggt gctggtggct gaatggctct acgtcccctt tggttgccac gggatgcttg 360
gaaactgtaca tgaggacctc ggggtggcct ggggtgcagag ggaggggagc gtcccgcgg 420
ggatcaaaaag aaaggaaggg ggtgccagga gggagcctct cccggctggc ctctagaac 480
tgcccgcgcg ctcccacgcg gacgccccg cctctgccag aaaccagcct tcttagaagg 540
gagggggggg aaagtgtgaa tgagaagttg ggggcggagc gcgcggggga gggccgctg 600
ccaggaacgc tcggccaagg ctggcgcccg gcccgccggt cgggcagcct cgcgccgcgc 660
tttgtctccc tctcggtagg tctcggcggg tcctggaggc cccagctcca agcccgcct 720
ccgcagcccc tcctcgcgcc tccgcgcaca gcctttcagt gcagagtagt gactaaacat 780
tacaagaaga ccggccgggc agttccagga atcggggggc ggggcgtact ggccgggtaa 840
ataccgcgcg gcggccctc cgaggcggct ctaactctga ctctacactc gcccgctcct 900
acgaccgctg tctctcggg ctcccggagc cccccttccc ggcccagctc tccgtcaggg 960
tcccctgccc aggtcctttg cctgattcgc ccaggagtgc gcctcatcgg cccggggagc 1020
agcgaagcca gagggggcgc acgcacgggg agcccctttg tagacttoac ggetgccaac 1080
atctggggcg agcgcgagcc actgctgggc gccgcctcgc ctccggggacc ataggaggcg 1140

```

-continued

```

cagccccaag gccggagatt tcgcttcggg actaggtagg aaggaggggc gcggtgtggg 1200
gaagggtggg gccatcggtc cagctcggga gcttttcccg gttctcctc cccttcccg 1260
gtcattcccg gtagggagg gacgaggcag ggggcagagc ggatgagaac cgaagatccc 1320
tgattcccg catactcaga ctggggccct cgggtttctc ctgtcccctc tctcacatat 1380
ctcgggtttg gcacccccct tttttcggc tcgccactga ggacaccgga ctgagaggcg 1440
ccctgagcgt ccctagggct cttgtgtctc tccccatcct gcccgctctc ctggagacc 1500
aacttcacg cgcgagtttt ctctgggct cctcctaggg cgggcagggg aagagactgt 1560
ctggggttg ccggcagtga ccgaggacag tcgagttccg cgaggtggct gggcctgaga 1620
cacggtctaa agcggggcaa aggggtgccc cgggcgctag gcggagctg gagggccggg 1680
cacgctggag gttccgggc actcacgctc ctccagcttt gctctctgca gctcccggg 1740
atgcggtagc ggccgctgtg cggaggccgc gaagcagctg cagccaccgc cgcgcagatc 1800
cac 1803

```

```

<210> SEQ ID NO 6
<211> LENGTH: 990
<212> TYPE: DNA
<213> ORGANISM: MURINE
<220> FEATURE:
<221> NAME/KEY: promoter
<222> LOCATION: (-63)...(927)

```

```

<400> SEQUENCE: 6
ggggggcggg gcgtactggc cgggtaaata cccgcgcgcg cggcctccga ggcggctcta 60
actctgactc tacactcgcc cgctcctacg accgctgtct ctccgggctc ccggacgccc 120
ccttcccggc ccagctctcc gtcgaggctc ctgcgccagg tcctttgcct gattcgccca 180
ggagtgcgcc tcatcgcccc ggggagcagc gaagccagag ggggcgcacg cacggggagc 240
ccctttgtag acttcacggc tgccaacatc tgggcgcagc gcgagccact gctgggcgcc 300
gcctgcctc ggggaccata ggaggcgcag cccaaggcc ggagatttcg cttcgggact 360
aggtaggaag gaggggcgcg gtgtgggaa ggggtggggc atcggctcag ctccgggact 420
tttccgggtt tctcctccc tccccgggtc attcccggta gggaggggac gaggcagggg 480
gcagagcggg tgagaaccga agatccctga ttcccgtcat actcagactg gggccctcgg 540
gtttctcctg tcccctctc cacatatctc gggtttgca cccccctttt ttcgccctcg 600
ccactgagga caccggactg agaggcgccc tgagcgtccc tagggctctt gtgtctctcc 660
ccatcctggc cgcgctcctg gagaccacac ttccacgctc gagttttctc tgggcgtcct 720
cctagggcgg gcaggggaag agactgtctg gggttggccg gcagtgaacc aggacagtcg 780
agttccgca ggtggctggg cctgagacac ggtctaaagc ggggcaaagg ggtgccccgg 840
gcgctaggcg gaggtggag gcccgggcac gctggagggt tccgggcaact cacgcgctc 900
acgctttgct ctctgcagct ccccgggatg cggtagcggc cgtgtgcgg aggccgcgaa 960
gcagctgcag ccaccgccgc gcagatccac 990

```

```

<210> SEQ ID NO 7
<211> LENGTH: 1024
<212> TYPE: DNA
<213> ORGANISM: MURINE
<220> FEATURE:

```

-continued

```

<221> NAME/KEY: promoter
<222> LOCATION: (-97)...(927)

<400> SEQUENCE: 7

ttacaagaag accggccggg cagttccagg aatcgggggg cggggcgtag tggccgggta    60
aataccgcg cgcgcggcct ccgagggcgc tctaactctg actctacact cgcccgcctc    120
tacgaccgct gtctctccgg gctcccggac gcccccttcc cggcccagct ctccgctcag    180
gtccctcgcc caggtccttt gcctgattcg cccaggagtg cgcctcatcg gcccggggag    240
cagcgaagcc agagggggcg cacgcacggg gagccccctt gtagacttca cggctgccaa    300
catctggggc cagcgcgagc cactgctggg cgccgcctcg cctcggggac cataggaggc    360
gcagcccca ggccggagat ttcgcttcgg gactaggtag gaaggagggg cgcgggtgtg    420
ggaaggggtg gggcatcggt ccagctcggg agcttttccc ggtttctcct ccccttcccg    480
ggtcattccc ggtagggagg ggacgaggca gggggcagag cggatgagaa ccgaagatcc    540
ctgattcccg tcatactcag actggggccc tcgggtttct cctgtcccct ctctcacata    600
tctcgggttt ggcaccccc ttttttcgcc ctgcacctg aggacaccgg actgagaggc    660
gccctgagcg tccttagggc tcttgtgtct ctccccatcc tggccgcgct cctggagacc    720
caacttccac gcgcgagttt tctctgggcy tcctcctagg gcgggcaggg gaagagactg    780
tctgggggtg gccggcagtg accgaggaca gtcgagttcc gcgaggtggc tgggcctgag    840
acacggtcta aagcggggca aaggggtgcc ccgggcgcta ggcggaggct ggagggccgg    900
gcacgctgga gggttccggg cactcacgcy cctcacgctt tgctctctgc agctccccgg    960
gatgcggtag cggccgctgt gcggaggcgg cgaagcagct gcagccaccg ccgcgcagat   1020
ccac                                                                    1024

```

```

<210> SEQ ID NO 8
<211> LENGTH: 201
<212> TYPE: DNA
<213> ORGANISM: MURINE
<220> FEATURE:
<221> NAME/KEY: promoter
<222> LOCATION: (-97)...(104)

<400> SEQUENCE: 8

ttacaagaag accggccggg cagttccagg aatcgggggg cggggcgtag tggccgggta    60
aataccgcg cgcgcggcct ccgagggcgc tctaactctg actctacact cgcccgcctc    120
tacgaccgct gtctctccgg gctcccggac gcccccttcc cggcccagct ctccgctcag    180
gtccctcgcc caggtccttt g                                                                    201

```

```

<210> SEQ ID NO 9
<211> LENGTH: 1014
<212> TYPE: DNA
<213> ORGANISM: MURINE
<220> FEATURE:
<221> NAME/KEY: promoter
<222> LOCATION: (-87)...(927)

<400> SEQUENCE: 9

accggccggg cagttccagg aatcgggggg cggggcgtag tggccgggta aataccgcg    60
cgcgcggcct ccgagggcgc tctaactctg actctacact cgcccgcctc tacgaccgct    120
gtctctccgg gctcccggac gcccccttcc cggcccagct ctccgctcag gtcctcgcc    180

```

-continued

```

caggtccttt gcctgattcg cccaggagtg cgcctcatcg gcccggggag cagcgaagcc 240
agagggggcg cacgcacggg gagccccctt gttagacttca cggctgcaa catctgggcg 300
cagcgcgagc cactgctggg cgcgcctcg cctcggggac cataggaggc gcagcccaa 360
ggccggagat ttcgcttcgg gactaggtag gaaggagggg cgcggtgtgg ggaagggtgg 420
gggcatcggg ccagctcggg agcttttccc ggtttctcct ccccttcccg ggtcattccc 480
ggtaggaggg ggacgaggca gggggcagag cggatgagaa ccgaagatcc ctgattcccg 540
tcatactcag actggggccc tcgggtttct cctgtcccct ctctcacata tctcgggttt 600
ggaccccccc ttttttcgcc ctgcgcaacty aggacaccgg actgagaggc gccctgagcg 660
tccttagggc tcttgtgtct ctccccatcc tggccgcgct cctggagacc caacttccac 720
gcgcgagttt tctctgggcg tctcctcctag gcgggcaggg gaagagactg tctggggttg 780
gccggcagtg accgaggaca gtcgagttcc gcgaggtggc tgggcctgag acacggctta 840
aagcggggca aaggggtgcc ccgggcgcta ggcggaggct ggagggccgg gcacgctgga 900
gggttcggg cactcagcg cctcagcgtt tgctctctgc agtcccccg gatgcggtag 960
cggccgctgt gcggaggccg cgaagcagct gcagccaccg ccgcccagat ccac 1014

```

```

<210> SEQ ID NO 10
<211> LENGTH: 191
<212> TYPE: DNA
<213> ORGANISM: MURINE
<220> FEATURE:
<221> NAME/KEY: promoter
<222> LOCATION: (-87)...(104)

```

```

<400> SEQUENCE: 10

```

```

accggccggg cagttccagg aatcgggggg cggggcgta tggccgggta aataccgcg 60
cgcgcccct ccgagggcgc tctaactctg actctacact cggccgctcc tacgaccgct 120
gtctctccg gctcccggac gcccccttc cggcccagct ctccgctgag gtcctctgcc 180
caggtccttt g 191

```

```

<210> SEQ ID NO 11
<211> LENGTH: 433
<212> TYPE: DNA
<213> ORGANISM: MURINE
<220> FEATURE:
<221> NAME/KEY: promoter
<222> LOCATION: (-275)...(158)

```

```

<400> SEQUENCE: 11

```

```

caggaacgct cggccaagc tggcgcccg cccgcccgtc gggcagctc gcgcccgct 60
ttgtctcct ctcggtgagt ctcggcgggt cctggaggcc ccagctcaa gcccgccctc 120
cgcagcccc ccctcgcct ccgcccagc ctttcagtg cagagtagtg actaaacatt 180
acaagaagc cggccgggca gttccagaa tcggggggcg gggcgtactg gccgggtaaa 240
taccgcgcg cgcggcctcc gaggcggctc taactctgac tctacactcg cccgctccta 300
cgaccgctgt ctctccgggc tcccggagc ccccttccc gccagctct cgtcagagt 360
ccctcgccea ggtcctttgc ctgattcgcc caggagtgc cctcatcggc ccggggagca 420
gcgaagccag agg 433

```

-continued

```

<210> SEQ ID NO 12
<211> LENGTH: 1088
<212> TYPE: DNA
<213> ORGANISM: MURINE
<220> FEATURE:
<221> NAME/KEY: promoter
<222> LOCATION: (-161)...(927)

<400> SEQUENCE: 12

gccctcgcga gccctccct cgcctccgc gcacagcctt tcagtgcaga gtagtgacta    60
aacattacaa gaagaccggc cgggcagttc caggaatcgg gggcgggggc gtactggccg    120
ggtaaatacc cgcgcgcgcg gcctccgagg cggctctaac tctgactcta cactcgcccg    180
ctctacgac cgctgtctct cgggctccc ggacgcccc ttcccggccc agctctccgt    240
cgaggtccct cccccaggtc ctttgctga ttgcgccagg agtgccctc atcgcccgg    300
ggagcagcga agccagaggg ggcgcacgca cggggagccc cttttagac ttcacggctg    360
ccaacatctg ggcgcagcgc gagccactgc tgggcgcgc ctcgcctcgg ggaccatagg    420
agggcagcc ccaagggcgg agatttcgct tcgggactag gttagaagga ggggcgcggt    480
gtggggaagg gtgggggcat cggtcacgct cgggagcttt tcccggtttc tcctcccctt    540
cccgggtcat tcccggtagg gaggggacga ggcagggggc agagcggatg agaaccgaag    600
atcctgatt cccgtcatac tcagactggg gccctcgggt ttctctgtc cctctctca    660
catatctcgg gtttgacc ccccttttt cgcctcggc actgaggaca cggactgag    720
aggcgcctg agcgtcccta gggctcttgt gtctctccc atcctggccg cgtcctgga    780
gacccaactt ccacgcgcga gttttctctg ggcgtcctcc tagggcgggc aggggaagag    840
actgtctggg gttggccgc agtgaccgag gacagtcgag tccgcgagg tggtggggc    900
tgagacacgg tctaaagcgg ggcaaaggg tgccccgggc gctagggcga ggctggagg    960
ccgggcacgc tggaggggtc cgggactca cgcgcctcac gcttctctct ctgcagctcc    1020
ccgggatgcg gtagcggccg ctgtgcggag gccgcgaagc agctgcagcc accgccgcgc    1080
agatccac                                         1088

```

```

<210> SEQ ID NO 13
<211> LENGTH: 9
<212> TYPE: DNA
<213> ORGANISM: MURINE
<220> FEATURE:
<221> NAME/KEY: promoter
<222> LOCATION: (-74)...(-66)
<223> OTHER INFORMATION: STAT-BINDING SITE AT -74 TO -66
<220> FEATURE:
<221> NAME/KEY: promoter
<222> LOCATION: (0)...(0)
<220> FEATURE:
<221> NAME/KEY: mutation
<222> LOCATION: (0)...(0)
<223> OTHER INFORMATION: STAT-BINDING SITE AT -74 TO 66

```

```

<400> SEQUENCE: 13

```

```

ttccaggaa

```

9

```

<210> SEQ ID NO 14
<211> LENGTH: 9
<212> TYPE: DNA
<213> ORGANISM: MURINE
<220> FEATURE:
<221> NAME/KEY: mutation

```

-continued

<222> LOCATION: (-74)...(66)

<400> SEQUENCE: 14

atcgacgat

9

<210> SEQ ID NO 15

<211> LENGTH: 27

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: PRIMER

<400> SEQUENCE: 15

cagtagaatc cgctctcctg cagcttg

7

<210> SEQ ID NO 16

<211> LENGTH: 27

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: PRIMER

<220> FEATURE:

<221> NAME/KEY: promoter

<222> LOCATION: (0)...(0)

<220> FEATURE:

<221> NAME/KEY: promoter

<222> LOCATION: (0)...(0)

<220> FEATURE:

<221> NAME/KEY: promoter

<222> LOCATION: (0)...(0)

<220> FEATURE:

<221> NAME/KEY: promoter

<222> LOCATION: (0)...(0)

<220> FEATURE:

<221> NAME/KEY: promoter

<222> LOCATION: (0)...(0)

<220> FEATURE:

<221> NAME/KEY: promoter

<222> LOCATION: (0)...(0)

<400> SEQUENCE: 16

ctcgcttttg gagctgaagg tcttgag

7

<210> SEQ ID NO 17

<211> LENGTH: 27

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: PRIMER

<400> SEQUENCE: 17

cttctacct agtcccgaag cgaaatc

7

<210> SEQ ID NO 18

<211> LENGTH: 26

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: PRIMER

<400> SEQUENCE: 18

cagatgttg cagccgtgaa gtctac

6

<210> SEQ ID NO 19

<211> LENGTH: 28

<212> TYPE: DNA

-continued

<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: PRIMER

<400> SEQUENCE: 19
gcgggcgagt gtagagtcag agttagag 8

<210> SEQ ID NO 20
<211> LENGTH: 29
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: PRIMER

<400> SEQUENCE: 20
cgattcctgg aactgcccgg ccggtcttc 9

<210> SEQ ID NO 21
<211> LENGTH: 29
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: PRIMER

<400> SEQUENCE: 21
ctcagtgggc tttctgacct gccctcttg 9

<210> SEQ ID NO 22
<211> LENGTH: 28
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: PRIMER

<400> SEQUENCE: 22
gactacacag agtagcttgg gctaggag 8

<210> SEQ ID NO 23
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: SENSE PRIMER

<400> SEQUENCE: 23
catcgcgacg cccccgcctc t 1

<210> SEQ ID NO 24
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: PRIMER

<400> SEQUENCE: 24
gaaaccgag ggcccagtc tg 2

<210> SEQ ID NO 25
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: MURINE
<220> FEATURE:
<221> NAME/KEY: promoter
<222> LOCATION: (-77)...(-57)

-continued

<400> SEQUENCE: 25

cagttccagg aatcgggggg c

1

<210> SEQ ID NO 26

<211> LENGTH: 21

<212> TYPE: DNA

<213> ORGANISM: MURINE

<220> FEATURE:

<221> NAME/KEY: promoter

<222> LOCATION: (0)...(0)

<223> OTHER INFORMATION: MUTATIONS AT POSITIONS -74, -71, -69, & -66

<400> SEQUENCE: 26

cagatcgacg attcgggggg c

1

<210> SEQ ID NO 27

<211> LENGTH: 26

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: OLIGONUCLEOTIDES

<400> SEQUENCE: 27

gatcgaactg accgcccgcc gcccg

6

<210> SEQ ID NO 28

<211> LENGTH: 30

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: PRIMERS

<400> SEQUENCE: 28

gacgttccta aaagcatgca tgtcaccag

0

<210> SEQ ID NO 29

<211> LENGTH: 30

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: PRIMERS

<400> SEQUENCE: 29

ggatctgccc gccggtggct gcagctgctt

0

<210> SEQ ID NO 30

<211> LENGTH: 9

<212> TYPE: DNA

<213> ORGANISM: MURINE

<220> FEATURE:

<221> NAME/KEY: promoter

<222> LOCATION: (-97)...(-89)

<223> OTHER INFORMATION: STAT-BINDING SITE AT -97 TO -89

<400> SEQUENCE: 30

ttacaagaa

9

1-75. (canceled)

76. A method of treating an autoimmune disease, immune disease, or an inflammatory condition in a human subject, comprising:

genetically modifying a gp-130-responsive cell of a human subject having an autoimmune disease, immune disease, or inflammatory condition with a nucleic acid construct comprising a SOCS-3 promoter sequence, or fragment thereof, operatively linked, in a transcriptional unit, to a DNA sequence encoding a functional anti-inflammatory cytokine of the gp130 subunit signaling cytokine family linked to a functional secretory signal; and

causing the cell, in vivo, to transcribe from said transcriptional unit, in response to a pro-inflammatory cytokine of the gp130 signaling subunit cytokine family, a functional mRNA transcript, whereby the anti-inflammatory cytokine is produced and secreted in response to the pro-inflammatory cytokine, and one or more symptoms of the autoimmune disease, immune disease, or inflammatory condition is improved.

77. The method of claim 76, wherein the cell is a pituitary, adrenal, hypothalamic, intestinal, kidney, liver, immune-competent, or bone-forming cell.

78. The method of claim 76, wherein the cell is a hepatocyte, lymphocyte, chondrocyte, neuron, intestinal epithelial, corticotroph, somatotroph, lactotroph, or gonadotroph cell.

79. The method of claim 76, wherein the cell is a cell derived from a pituitary tumor, adrenal tumor, hypothalamic tumor, or liver tumor.

80. The method of claim 76, wherein the SOCS-3 promoter sequence is a murine SOCS-3 promoter having a nucleotide sequence (SEQ. ID. NO:1), or an operative fragment or non-murine homologue thereof, or an operative derivative of any of these.

81. The method of claim 76, wherein said transcriptional unit further comprises a DNA sequence encoding a reporter protein.

82. The method of claim 81, wherein the encoded reporter protein is a fluorescent or light-emitting protein.

83. The method of claim 82, wherein the encoded fluorescent or light-emitting protein is a green fluorescent protein, yellow fluorescent protein, blue fluorescent protein, phycobiliprotein, luciferase, or apoaquorin.

84. The method of claim 76, further comprising at least one insulator element flanking said transcriptional unit.

85. The method of claim 84, wherein at least one of said insulator element(s) is a chicken O-globin insulator element.

86. The method of claim 76, wherein the pro-inflammatory cytokine is IL-6 or LIF.

87. The method of claim 76, wherein the anti-inflammatory cytokine is IL-11.

88. The method of claim 76, wherein the autoimmune disease, immune disease, or inflammatory condition is Crohn's disease, ulcerative colitis, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, Grave's disease, or a neuroendocrinological response to stress.

89. The method of claim 76, further comprising obtaining the gp130-responsive cell from a tissue of the human

subject; genetically modifying the cell in vitro; and re-implanting the genetically modified cell into the tissue of the human subject.

90-121. (canceled)

122. A method of treating an autoimmune disease, immune disease, or inflammatory condition in a human subject, comprising:

obtaining a gp130-responsive cell from a tissue of a human subject having an autoimmune disease, immune disease, or inflammatory condition;

transfecting said cell with a nucleic acid construct comprising a murine SOCS-3 promoter having a nucleotide sequence (SEQ. ID. NO:1), or an operative fragment or non-murine homologue thereof, or an operative derivative of any of these, operatively linked, in a transcriptional unit, to a DNA sequence encoding a functional anti-inflammatory cytokine of the gp130 subunit signaling cytokine family linked to a functional secretory signal; and

re-implanting said cell within the tissue of said human subject, whereby the anti-inflammatory cytokine is produced and secreted, in vivo, in response to a pro-inflammatory cytokine of the gp130 subunit signaling cytokine family, and one or more symptoms of the autoimmune disease, immune disease, or inflammatory condition is improved.

123. The method of claim 122, wherein the cell is a pituitary, adrenal, hypothalamic, intestinal, kidney, liver, immune-competent, or bone-forming cell.

124. The method of claim 122, wherein the cell is a hepatocyte, lymphocyte, chondrocyte, intestinal epithelial, corticotroph, somatotroph, lactotroph, or gonadotroph cell.

125. The method of claim 122, wherein the cell is a cell derived from a pituitary tumor, adrenal tumor, hypothalamic tumor, or liver tumor.

126. The method of claim 122, wherein said transcriptional unit further comprises a DNA sequence encoding a reporter protein.

127. The method of claim 126, wherein the encoded reporter protein is a fluorescent or light-emitting protein.

128. The method of claim 127, wherein the fluorescent or light-emitting protein is a green fluorescent protein, yellow fluorescent protein, blue fluorescent protein, phycobiliprotein, luciferase, or apoaquorin.

129. The method of claim 122, further comprising at least one insulator element flanking said transcriptional unit.

130. The method of claim 129, wherein at least one of said insulator element(s) is a chicken O-globin insulator element.

131. The method of claim 122, wherein the anti-inflammatory cytokine is IL-11.

132. The method of claim 122, wherein the pro-inflammatory cytokine is IL-6 or LIF.

133. The method of claim 122, wherein the autoimmune disease, immune disease, or inflammatory condition is Crohn's disease, ulcerative colitis, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, Grave's disease, an allergic or anaphylactic reaction, or a neuroendocrinological response to stress.

* * * * *